Transdermal pharmaceutical preparations for the treatment of cancer

JP2023552387A5Inactive Publication Date: 2024-12-06パイク セラピューティクスインコーポレイテッド
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023533900
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-12-03
Filing Date
2021-12-02
Publication Date
2024-12-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current drug delivery systems for cannabinoids like THC and CBD, particularly for treating cancer, face challenges such as hepatic first-pass metabolism, variable pharmacological responses, and the need for frequent dosing, which can lead to peak and trough plasma concentrations and adverse effects.

Method used

Transdermal delivery systems, including patches and compositions, provide continuous and controlled release of THC and CBD through the skin, avoiding hepatic metabolism and reducing administration frequency, thereby maintaining stable plasma concentrations and minimizing side effects.

Benefits of technology

Transdermal delivery offers a patient-friendly, convenient, and effective method for treating cancer by ensuring consistent drug levels, reducing adverse effects, and improving compliance through less frequent dosing.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure relates to methods of treating cancer, and more particularly to an active agent selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination thereof, in a formulation for transdermal delivery in the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Cross - reference to related applications This application claims the benefit of U.S. Application No. 63 / 120,932, filed December 3, 2020, which is hereby incorporated by reference in its entirety.

[0002] In certain embodiments, the present disclosure relates to methods for treating cancer, and more particularly to an active agent selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination thereof in a formulation for transdermal delivery in the treatment of cancer.

Background Art

[0003] Cancer is the second leading cause of death in the United States. In an estimate for 2014, approximately 585,000 people died of cancer and 1.6 million new cases were diagnosed (Non - Patent Document 1). Glioblastoma multiforme (GBM) is the most common and most lethal primary brain tumor affecting adults. Despite advances made in surgery, radiology, and chemotherapy for this grade IV astrocytoma, the prognosis remains very poor: the median survival from diagnosis remains 9 - 15 months and less than 10% of patients survive beyond 5 years. Over the past decade, survival rates in the treatment of this disease have not significantly progressed, and the standard after surgery is administration of chemoradiotherapy with temozolomide followed by 6 cycles of continuous chemotherapy with temozolomide. Δ9 - Tetrahydrocannabinol (THC) and cannabidiol (CBD) have shown a clear synergistic antitumor effect with temozolomide and radiotherapy in pre - clinical glioma models. THC and CBD bind to and activate type 1 and type 2 cannabinoid receptors (CB1 expressed in specific neuronal regions of the brain and CB2 expressed in the immune system and glial cells), and by activating these receptors, have a variety of biological effects. Activation of these receptors initiates a signaling pathway called the endoplasmic reticulum stress response, which generates tumor cell autophagy by activating TRB3.

[0004] Cannabis (marijuana) is a Schedule I drug in the United States. Cannabis is a flowering plant containing more than 400 types of phytonutrients (micronutrients). More than 100 types of terpenoids, essential oils, antioxidants, and cannabinoids are extracted from the plant. Of all the phytochemicals, only tetrahydrocannabinol (THC) showed significant psychoactive effects. Many research papers have been published on THC due to its psychoactive effects and therapeutic effects. In addition to THC, other components such as cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabigerol (CBG), tetrahydrocambivarin (THCV), and delta-9-tetrahydrocannabinol (delta-9THC) have also been studied, and have been shown to have therapeutic effects without psychoactive effects. Cannabis and its derivatives have been shown to be used alone or in combination with other activators to treat pain, type 2 related metabolic disorders, hypotension, Dravet syndrome, Lennox-Gastaut syndrome (LGS), epilepsy, nausea, AIDS-related pain and wasting, arthritis and rheumatism, migraines, muscle spasms associated with multiple sclerosis and paralysis, alcohol and drug withdrawal, stress and depression, asthma, fibromyalgia, inflammatory pain, and pain and / or inflammation associated with chemotherapy. FDA-approved Marinol and Syndros contain delta-9-THC and are currently used for chemotherapy-related nausea, vomiting, and loss of appetite. In clinical trials, Sativex (a cannabinoid extract oral mucosal spray containing THC and CBD) showed improvement in neuropathic pain and sleep quality. Furthermore, in April 2016, the FDA designated cannabidiol as an orphan drug for the treatment of tuberous sclerosis syndrome (TSC), Dravet syndrome, and Lennox-Gastaut syndrome. Cannabidiol is an effective oral medication for pain and inflammation (Non-Patent Document 2).

[0005] The potential usefulness of cannabinoids in cancer treatment is of great interest. Recently, both CB1 and CB2 have been found to be expressed in many cancer types, but both receptors were often undetectable at the site of cancer origin before neoplastic transformation (Non-Patent Literature 3). Further evidence for the role of the endocannabinoid system in neoplasia was obtained when Wang and collaborators showed that CB1 has tumor suppressor function in a genetically modified mouse model of colorectal cancer (Non-Patent Literature 4). CB1 is upregulated in hepatocellular carcinoma and Hodgkin lymphoma, and the degree of CB1 overexpression correlated with disease severity in epithelial ovarian cancer (Non-Patent Literature 5). CB2 has also been found to be overexpressed in HER2+ breast cancer and glioma (Non-Patent Literature 6). Overexpression of both CB1 and CB2 has been shown to correlate with poor prognosis in stage IV colorectal cancer (Non-Patent Literature 7). Administration of cannabinoids such as D8-THC, D9-THC, and CBD inhibited DNA synthesis and proliferation in lung adenocarcinoma in cultured cells and mouse tumor models (Non-Patent Literature 8). Similar effects were observed in both in vitro and in vivo models of various other cancers, including glioma, breast cancer, pancreatic cancer, prostate cancer, colorectal cancer, and lymphoma (Non-Patent Literature 9). Behind these findings, various mechanisms of action have been proposed, including but not limited to cell cycle arrest, induction of apoptosis, and inhibition of angiogenesis, migration, adhesion, invasion, and metastasis (Non-Patent Literature 10). See Non-Patent Literature 11.

[0006] Extensive preclinical studies exist demonstrating CBD as an effective anticancer agent, either alone or in combination with other cannabinoids, chemotherapy, and / or radiotherapy. Improved drug delivery systems for CBD and / or THC that can overcome the drawbacks associated with oral delivery are needed. Transdermal and / or topical delivery of CBD and / or THC, its free base, its salts, its isomers, its amorphous, its crystalline, its cocrystals, its prodrugs, its analogues, its derivatives, its synthetics, its biosynthetic, its active metabolites, its solid solutions, its polymorphs, its stereoisomers, its coatings, its ion pairs, or its solutions in solvents, either alone or in combination thereof, can address the challenges associated with oral drug delivery and may be useful, for example, in the treatment, prevention, and / or control of cancer. All references cited herein are incorporated herein by reference in their entirety. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] American Cancer Society,Cancer Facts&Figures 2014 [Non-Patent Document 2] Costa, B. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. European Journal of Pharmacology.Volume 556,Issues 1-3,5 February 2007,Pages 75-83 [Non-Patent Document 3] Sarfaraz,S.;Adhami,VM;Syed,DN;Afaq,F.;Mukhtar,H.Cannabinoids for Cancer Treatment:Progress and Promise.Cancer Res.2008,68,339-342

Outdoor Tools 4

Direct Environment 5

Outdoor Configuration6

Direct Environment 7

Non - Patent Document 8

Non - Patent Document 9

Non - Patent Document 10

Non - Patent Document 11

Summary of the Invention

[0008] This disclosure provides compositions and methods for treating and / or preventing and / or controlling cancers, such as glioblastoma and GBM, using transdermal drug delivery. In transdermal drug delivery, a transdermal patch or transdermal composition is applied topically to the skin surface. During the duration of topical application of the transdermal patch or transdermal composition, the drug is continuously released and delivered through intact skin (via transcellular, intercellular, and transadnexal pathways) to achieve its effect. Thus, once a transdermal composition or transdermal patch is applied, the drug can be delivered into the systemic circulation throughout the day, or even beyond a day, depending on the duration of application, and the duration of application may even be up to one week.

[0009] Highly purified tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof can be applied topically to the skin via transdermal delivery such as transdermal compositions, preparations, or patches, thereby delivering the drug for the duration of topical application. If necessary, the frequency of topical application may be once daily, once every two days, once every three days, once every four days, once every five days, or once a week. Therefore, transdermal delivery can overcome the limitations of multiple-dose regimens of oral delivery by reducing the frequency of administration.

[0010] Furthermore, with transdermal drug delivery, the drug is delivered slowly and continuously throughout the duration of topical application, and therefore there are no peaks and troughs in drug plasma concentration associated with multiple daily doses. Thus, transdermal delivery of highly purified tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination thereof allows patients to experience the therapeutic effects of the drug over a long period without dramatically altering drug plasma concentrations.

[0011] In transdermal delivery, drugs are delivered to the systemic circulation through the skin, bypassing first-pass hepatic metabolism. Therefore, less drug is needed to achieve the desired therapeutic activity, resulting in fewer adverse effects or side effects. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are highly lipophilic and undergo first-pass hepatic metabolism after oral administration. Consequently, only 10% to 20% of the administered dose reaches the systemic circulation. Therefore, compared to oral administration, transdermal delivery allows low doses of tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof to deliver the desired therapeutic effect at a lower dose than oral administration. Furthermore, transdermal delivery is easy, non-invasive, and convenient. Administration of transdermal patches or compositions does not require medical supervision, as patients can apply the patches or compositions topically themselves.

[0012] With respect to tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, drug plasma concentrations can be controlled by controlling the rate of drug delivery from transdermal compositions or patches, so inter-patient variability in pharmacological responses is expected to be smaller with transdermal delivery. Transdermal delivery allows for the delivery of small amounts of tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof over a longer period than oral administration. Transdermal formulations of tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof can also deter abuse more than immediate-release formulations. Furthermore, in the event of any adverse effects, side effects, or urgent transdermal delivery, treatment can be terminated at any time by removing the transdermal patch or composition from the skin.

[0013] For the reasons stated above for the treatment and / or prevention and / or control of cancer, transdermal delivery can provide a more patient-friendly, simplified, and convenient treatment regimen than conventional delivery systems. Transdermal delivery can reduce the frequency of administration of highly purified tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof. If necessary, the frequency of administration may be once daily, once every two days, once every three days, once every four days, once every five days, once every six days, or once a week. Transdermal administration of drug combinations allows for the simultaneous delivery of two or more drugs. If necessary, the frequency of administration of transdermal patches or compositions containing drug combinations may be once daily, once every two days, once every three days, once every four days, once every five days, once every six days, or once a week. This would lead to greater patient compliance.

[0014] The continuous drug delivery methods and systems disclosed herein can deliver activators in several different ways, such as intradermal or subcutaneous application, or injectable therapy via transdermal or topical application. Infusion therapy involves administering drugs using a sterile, thin tube, such as a catheter, that is inserted into and fixed in the body. Pump delivery systems and any other delivery systems (e.g., depot injections and portable pumps) that deliver continuous infusions may be used for this purpose. Continuous drug delivery systems and methods may also include, for example, transdermal systems. In transdermal drug delivery, a transdermal patch or transdermal composition is applied topically to the skin surface. During the duration of topical application of the transdermal patch or transdermal composition, the drug is continuously released and delivered through intact skin (via transcellular, intercellular, and transadnexal pathways) to achieve its effect. Thus, once a transdermal composition or transdermal patch is applied, the drug can be delivered into the systemic circulation throughout the day, or even beyond a day, depending on the duration of application, and the duration of application may even be up to one week.

[0015] In continuous drug delivery, the active agent is continuously released and delivered to the patient to achieve a systemic effect. Thus, once applied, a continuous drug delivery system can deliver the active agent to the systemic circulation for longer than one day, depending on the duration of its application, which may be through the day or even up to one week. Through continuous drug delivery, for example, purified tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof can be delivered during the duration of the application. The application period can be once a day, once every two days, once every three days, once every four days, once every five days, or once a week, as needed. Thus, continuous drug delivery can overcome the multiple-dose regimens of oral delivery by reducing the dosing frequency. In continuous drug delivery, the pharmaceutical composition containing the active agent is delivered slowly and continuously during the administration period, and thus there are no peaks and troughs in the drug plasma concentration of the active agent associated with multiple administrations such as oral administration in a day. Thus, for example, through the continuous drug delivery of tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, a patient can have the therapeutic effect of the drug over a long period without dramatically changing the drug plasma concentration.

[0016] In serial drug delivery using the systems and methods disclosed herein, the activator is delivered into the systemic circulation, avoiding first-pass hepatic metabolism, and therefore less drug is needed to achieve the desired therapeutic activity, resulting in fewer adverse effects or side effects. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are highly lipophilic and undergo first-pass hepatic metabolism after oral administration, so only 10% to 20% of the administered dose reaches the systemic circulation. Therefore, compared to oral administration, transdermal delivery allows low doses of tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof to provide the desired therapeutic effect at a lower dose than oral administration. Furthermore, using serial drug delivery systems and methods as disclosed herein is easy, non-invasive, and convenient. Serial administration of drug compounds does not require medical management because the patient can control the dosage themselves.

[0017] In certain embodiments, continuous drug delivery systems and methods as disclosed herein may include pump devices commonly used to deliver one or more fluids to a target individual. For example, medical infusion pump devices may be used to deliver drugs to a patient as part of a medical procedure. The activator(s) delivered by the infusion pump device may depend on the patient's condition and the desired treatment plan. For example, an infusion pump device is used to deliver insulin to the subcutaneous tissue and the vascular system of diabetic patients to regulate blood glucose levels. In some cases, the dosage of the drug delivered by the infusion pump can be calculated by the infusion pump system. In such cases, the infusion pump system may take into account many variables, including user input, when performing such calculations.

[0018] Other forms of continuous drug delivery systems and methods can utilize fluid delivery to a target individual. For example, insulin, glucagon, or other agents can be injected using a manual syringe or a single-use injection "pen". In some cases, injectable forms of glucagon are used in the emergency assistance of severe hypoglycemia when the affected person is unconscious or unable to orally ingest glucose for other reasons. The glucagon solution can be rapidly injected into the patient by intramuscular, intravenous, or subcutaneous injection, rapidly increasing the patient's blood glucose level.

[0019] One category of devices for delivering such fluids is the category of pumps developed for the administration of insulin and other agents for people suffering from both type I and type II diabetes. Some pumps configured as portable infusion devices can provide continuous drugs for the treatment of diabetes. Such therapies may include, for example, regular and / or continuous injection or infusion of insulin into the skin of a person with diabetes, providing an alternative to multiple daily injections of insulin using an insulin syringe or insulin pen. Such pumps may be outpatient / portable infusion pumps that can be worn by the user and may use a replaceable cartridge. Examples of such pumps and various features associated with such pumps are disclosed in U.S. Patent Application No. 13 / 557,163, U.S. Patent Application No. 12 / 714,299, U.S. Patent Application No. 12 / 538,018, U.S. Patent Application No. 13 / 838,617, U.S. Patent Application No. 13 / 827,707, and U.S. Patent No. 8,287,495, each of which is incorporated herein by reference in its entirety.

[0020] In certain embodiments disclosed herein, the continuous drug delivery system is a patch pump or micropump patch pump. For example, a patch pump or micropump patch pump is typically a small, portable pump that is carried directly on the skin under the user's clothing. Such pumps are generally positioned directly at the injection site so that no administration is required to deliver insulin or other drugs to the patient. Patch pumps are typically at least partially disposable, meaning they are worn for one or two days and then discarded for a new patch pump.

[0021] This disclosure provides pharmaceutical compositions for transdermal delivery formulations that include an active agent selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD), and combinations thereof. This disclosure provides pharmaceutical compositions for topical delivery formulations that include an active agent selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD), and combinations thereof. This disclosure provides pharmaceutical compositions in which THC is selected from the group consisting of its free base, its salts, its isomers, its amorphous form, its crystalline form, its cocrystalline form, its prodrug, its analogues, its derivatives, its synthetic form, its biosynthetic form, its natural form, its active metabolites, its polymorphs, its solid solutions, its coated forms, its stereoisomers, its solid solutions, its ion pairs, its solutions, its powders, and its liquids, either alone or in combination thereof. This disclosure provides pharmaceutical compositions in which CBD is selected from the group consisting of its free base, its salts, its isomers, its amorphous form, its crystalline form, its cocrystal form, its prodrug, its analogues, its derivatives, its synthetic form, its biosynthetic form, its natural form, its active metabolites, its polymorphs, its solid solutions, its coatings, its stereoisomers, its solid solutions, its ion pairs, its solutions, its powders, and its liquids, either alone or in combination thereof. This disclosure provides pharmaceutical compositions containing at least about 0.1% to about 80% (w / w) of the activator CBD. This disclosure provides pharmaceutical compositions containing at least about 0.1% to about 80% of the activator THC. This disclosure provides pharmaceutical compositions formulated as transdermal liquid formulations, transdermal semi-solid formulations, or transdermal polymer matrix formulations. This disclosure provides a pharmaceutical composition further comprising an effective amount of a carrier or component selected from the group consisting of its free base, its salt, its isomer, its amorphous form, its crystalline form, its cocrystalline form, its prodrug, its analogue, its derivative, its synthetic form, its biosynthetic form, its natural form, its active metabolite, its polymorph, its solid solution, its coating, its stereoisomer, its solid solution, its ion pair, its solution, its powder, or its liquid, either alone or in combination thereof.This disclosure provides pharmaceutical compositions containing an effective amount of a carrier or component selected from the group consisting of solvents, gelling agents, polymers, pressure-sensitive adhesive polymers, penetration enhancers, emollients, skin irritation reducers, buffers, pH stabilizers, solubilizers, suspending agents, dispersants, stabilizers, plasticizers, tackifiers, diluents, bulking agents, surfactants, antioxidants, oxidizing agents, and combinations thereof, in the range of 0.1% to 99.5% w / w or w / v. This disclosure provides pharmaceutical compositions in which the carrier is present in the range of 70% to 99% w / w or w / v. This disclosure provides pharmaceutical compositions that can be formulated as quantitative gels, quantitative sprays, gels, creams, solutions, emulsions, liquid compositions, semi-solid compositions, adhesive matrices in combination with polymers, or film-forming formulations. This disclosure provides pharmaceutical compositions that can be formulated as transdermal patches. This disclosure provides pharmaceutical compositions formulated as transdermal patches, the transdermal patches being selected from the group consisting of reservoir patches, multilayer transdermal matrix systems, microreservoir patches, matrix patches, drug-containing adhesive patches, matrix patches of adhesives combined with polymers, pressure-sensitive adhesive patches, sustained-release transdermal patches, liquid reservoir systems, microreservoir patches, Amco adhesive patches, and combinations thereof.This disclosure concerns endometrial cancer, breast cancer, ovarian cancer, cervical cancer, fallopian tube cancer, testicular cancer, primary peritoneal cancer, colon cancer, colorectal cancer, small intestine cancer, anogenital squamous cell carcinoma, melanoma, renal cell carcinoma, lung cancer, non-small cell lung cancer, stomach cancer, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, salivary gland cancer, esophageal squamous cell carcinoma, stomach cancer, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, lung squamous cell carcinoma, lung squamous cell carcinoma, stomach cancer, bladder cancer, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, The present invention provides pharmaceutical compositions for the treatment and / or prevention and / or control of cancer in patients, selected from the group consisting of head and neck cancer, head and neck squamous cell carcinoma, prostate cancer, pancreatic cancer, mesothelioma, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, head and neck cancer, head and neck squamous cell carcinoma, prostate cancer, pancreatic cancer, mesothelioma, Merkel cell carcinoma, sarcoma, glioblastoma, GBM, hematological cancers, such as multiple myeloma, B-cell lymphoma, T-cell lymphoma, Hodgkin lymphoma / primary mediastinal B-cell lymphoma, and chronic myeloid leukemia. This disclosure provides a pharmaceutical composition formulated as a transdermal preparation that can be administered in a dosage regimen selected from the group consisting of once daily, twice daily, three times daily, once every 1 to 8 hours, once every 1 to 24 hours, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every 8 to about 13 days, once every two weeks, and once every 15 to about 30 days. This disclosure also provides a pharmaceutical composition formulated as a topical preparation that can be administered in a dosage regimen selected from the group consisting of once daily, twice daily, three times daily, four times daily, five times daily, six times daily, once every 1 to 8 hours, once every 1 to 24 hours, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every 8 to about 13 days, once every two weeks, and once every 15 to about 30 days. This disclosure provides a pharmaceutical composition that may be formulated as a microneedle.This disclosure provides pharmaceutical compositions in which tetrahydrocannabinol (THC), cannabidiol (CBD), its free base, its salt, its isomer, its amorphous form, its crystalline form, its cocrystal, its prodrug, its analogue, its derivative, its synthetic form, its biosynthetic form, its natural form, its active metabolite, its polymorph, its solid solution, its coating, and combinations thereof are produced by synthetic pathways. This disclosure provides pharmaceutical compositions in which the tetrahydrocannabinol (THC), cannabidiol (CBD), or derivatives thereof are produced by synthetic pathways. This disclosure provides pharmaceutical compositions to be administered in combination with at least one further therapeutic agent selected from the group consisting of temozolomide, peptides, polypeptides, fusion proteins, nucleic acid molecules, small molecules, mimetic agents, synthetic drugs, inorganic molecules, organic molecules, biological therapies including chemotherapy, radiotherapy, hormone therapy, anti-angiogenic therapy, targeted therapy, and / or immunotherapy and surgery, and combinations thereof.

[0022] This disclosure provides a method for treating and / or preventing and / or controlling cancer in a patient, comprising the steps of selecting a patient in need of treatment and / or prevention and / or control of cancer, and applying topically a pharmaceutical composition disclosed herein. This disclosure provides a method for treating and / or preventing and / or controlling cancer in a patient, comprising the steps of selecting a patient in need of treatment and / or prevention and / or control of cancer, and applying topically a pharmaceutical composition disclosed herein. The cancers include endometrial cancer, breast cancer, ovarian cancer, cervical cancer, fallopian tube cancer, testicular cancer, primary peritoneal cancer, colon cancer, colorectal cancer, small intestine cancer, anogenital squamous cell carcinoma, melanoma, renal cell carcinoma, lung cancer, non-small cell lung cancer, gastric cancer, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, salivary gland cancer, esophageal squamous cell carcinoma, gastric cancer, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, and The present disclosure provides a method for treating and / or preventing and / or controlling cancer in a patient, selected from the group consisting of esophageal cancer, head and neck cancer, head and neck squamous cell carcinoma, prostate cancer, pancreatic cancer, mesothelioma, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, head and neck cancer, head and neck squamous cell carcinoma, prostate cancer, pancreatic cancer, mesothelioma, Merkel cell carcinoma, sarcoma, glioblastoma, GBM, hematological cancers, e.g., multiple myeloma, B-cell lymphoma, T-cell lymphoma, Hodgkin lymphoma / primary mediastinal B-cell lymphoma, chronic myeloid leukemia. The present disclosure provides a method in which the cancer is glioblastoma or GBM. This disclosure provides a method for the topical application of a transdermal pharmaceutical composition for the treatment and / or prevention and / or control of cancer in a patient, wherein the transdermal pharmaceutical composition is applied at intervals selected from the group consisting of once daily, once every two days, once every three days, once every four days, once every five days, once every six days, once every week, and once every ten days. This disclosure further provides a method for delivering the active agent of the transdermal pharmaceutical composition at a constant delivery rate over a set period of time. This disclosure further provides a method for delivering a stable absorption rate of the active agent of the transdermal pharmaceutical composition over a set period of time. This disclosure further provides a method for reaching a constant serum blood level of the active agent of the transdermal pharmaceutical composition over a set period of time.This disclosure further provides a method for reducing the temporal variation in the dose of the active agent of a transdermal pharmaceutical composition over a period of time. This disclosure further provides a method for delivering a plasma concentration of the active agent of a transdermal pharmaceutical composition within a therapeutic range over a period of time. This disclosure further provides a method for delivering a plasma concentration of the active agent of a transdermal pharmaceutical composition within a therapeutic range of approximately 0.01 ng / mL to approximately 500 ng / mL. This disclosure provides a method in which the transdermal pharmaceutical composition is in a dosage form selected from the group consisting of creams, lotions, gels, oils, ointments, suppositories, sprays, foams, liniments, aerosols, choke tablets and sublingual tablets, transdermal devices, and transdermal patches. This disclosure provides a method of administering a pharmaceutical composition in combination with at least one further therapeutic agent selected from the group consisting of temozolomide, peptides, polypeptides, fusion proteins, nucleic acid molecules, small molecules, mimetic agents, synthetic drugs, inorganic molecules, organic molecules, biological therapies including chemotherapy, radiotherapy, hormone therapy, anti-angiogenic therapy, targeted therapy, and / or immunotherapy and surgery, as well as combinations thereof.

[0023] This disclosure provides a pharmaceutical composition comprising: about 3% to about 15% of an activator selected from the group consisting of cannabidiol (CBD), its synthetic compounds, its biosynthetic compounds, its free base, its salt, its isomer, its amorphous form, its derivatives, and combinations thereof; about 3% to about 15% of an activator selected from the group consisting of tetrahydrocannabinol (THC), its synthetic compounds, its biosynthetic compounds, its free base, its salt, its isomer, its amorphous form, its derivatives, and combinations thereof; further comprising about 0% to about 97% of at least one solvent; about 0% to about 97% of at least one surfactant; optionally about 0% to about 97% of at least one permeabiliser; and / or optionally about 0% to about 97% of at least one activator selected from the group consisting of adhesives and / or polymers. This disclosure provides pharmaceutical compositions in which the activator is present in concentrations selected from the group consisting of approximately 1%, approximately 1.5%, approximately 2%, approximately 2.5%, approximately 3%, approximately 3.5%, approximately 4%, approximately 4.5%, approximately 5%, approximately 5.5%, approximately 6%, approximately 6.5%, approximately 7%, approximately 7.5%, approximately 8%, approximately 8.5%, approximately 9%, approximately 9.5%, approximately 10%, approximately 15%, approximately 20%, approximately 25%, approximately 30%, approximately 35%, approximately 40%, approximately 45%, and approximately 50% of the formulation. This disclosure provides a pharmaceutical composition in which the activator is present in concentrations selected from the group consisting of about 1% to about 10%, about 1% to about 9%, about 1% to about 8%, about 1% to about 7%, about 1% to about 6%, about 1% to about 5%, about 0.1% to about 50%, about 1% to about 20%, about 5% to about 25%, about 10% to about 20%, or about 15% to about 18%, about 30% to about 70%, and about 35% to about 65% of the formulation. This disclosure provides pharmaceutical compositions selected from the group consisting of THC, its free base, its salts, its isomers, its amorphous form, its crystalline form, its cocrystalline form, its prodrug, its analogues, its derivatives, its synthetic form, its biosynthetic form, its natural form, its active metabolites, its polymorphs, its solid solutions, its coatings, its stereoisomers, its solid solutions, its ion pairs, its solutions, its powders, and its liquids, either individually or in combination thereof.This disclosure provides pharmaceutical compositions in which CBD is selected from the group consisting of its free base, its salts, its isomers, its amorphous form, its crystalline form, its cocrystal form, its prodrug, its analogues, its derivatives, its synthetic form, its biosynthetic form, its natural form, its active metabolites, its polymorphs, its solid solutions, its coatings, its stereoisomers, its solid solutions, its ion pairs, its solutions, its powders, and its liquids, either individually or in combination thereof. This disclosure provides pharmaceutical compositions comprising, in a transdermal delivery formulation, one or more active agents selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD), its free base, its salts, its isomers, its amorphous form, its crystalline form, its cocrystal form, its prodrug, its analogues, its derivatives, its synthetic form, its biosynthetic form, its natural form, its active metabolites, its polymorphs, its solid solutions, its coatings, and combinations thereof.

[0024] This disclosure provides pharmaceutical compositions which are formulated as transdermal liquid formulations, transdermal semi-solid formulations, transdermal gelling agents, transdermal polymer matrix formulations, transdermal adhesive matrix formulations, transdermal film-forming gelling agents, transdermal film-forming spray formulations, multilayer transdermal matrix systems, infusion pump formulations, or transdermal drug-in-adhesive matrix formulations. This disclosure provides pharmaceutical compositions which provide continuous sustained delivery of the pharmaceutical composition to mitigate the peaks and troughs of the pharmacokinetic behavior of the active agent. This disclosure provides pharmaceutical compositions which result in continuous sustained delivery by administration to a patient via a route selected from the group consisting of parenteral, intravenous, subcutaneous, intramuscular, intrathecal, oral, buccal, mucosal, nasal, rectal, vaginal, transdermal, implantable, topical, and combinations thereof. This disclosure provides pharmaceutical compositions which result in continuous sustained delivery by intravenous or subcutaneous injection. This disclosure provides pharmaceutical compositions which result in continuous sustained delivery by subcutaneous injection. This disclosure provides pharmaceutical compositions that are delivered continuously by an infusion pump device. This disclosure provides pharmaceutical compositions that are delivered continuously by an outpatient / portable infusion pump that is attached to a patient and can use replaceable cartridges. This disclosure provides pharmaceutical compositions that are delivered continuously by a patch pump or micropump. This disclosure provides pharmaceutical compositions that are formulated as topical liquid formulations, topical semi-solid formulations, topical gel formulations, topical polymer matrix formulations, topical adhesive matrix formulations, topical film-forming gel formulations, infusion pump formulations, or topical film-forming spray formulations, external film-forming gel formulations, infusion pump formulations, or external film-forming spray formulations. This disclosure provides a pharmaceutical composition further comprising an effective amount of a carrier or component selected from the group consisting of its free base, its salt, its isomer, its amorphous form, its crystalline form, its cocrystalline form, its prodrug, its analogue, its derivative, its synthetic form, its biosynthetic form, its natural form, its active metabolite, its polymorph, its solid solution, its coating, its stereoisomer, its solid solution, its ion pair, its solution, its powder, or its liquid, either alone or in combination thereof.This disclosure provides a pharmaceutical composition containing an effective amount of a carrier or component selected from the group consisting of solvents, gelling agents, polymers, pressure-sensitive adhesive polymers, penetration enhancers, emollients, skin irritation reducers, buffers, pH stabilizers, solubilizers, suspending agents, dispersants, stabilizers, plasticizers, tackifiers, diluents, bulking agents, surfactants, antioxidants, oxidizing agents, and combinations thereof, in the range of 0.1% to 99.5% w / w or w / v.

[0025] This disclosure provides pharmaceutical compositions formulated as transdermal patches. This disclosure provides pharmaceutical compositions formulated as multilayer transdermal matrix systems, quantitative transdermal gels, quantitative transdermal sprays, film-forming gels, film-forming sprays, or quantitative aerosols. This disclosure provides pharmaceutical compositions formulated as topical patches. This disclosure provides pharmaceutical compositions formulated as quantitative gels, quantitative sprays, gels, creams, solutions, emulsions, liquid compositions, semi-solid compositions, adhesive matrices combined with polymers, or film-forming formulations. This disclosure provides pharmaceutical compositions formulated as transdermal patches, the transdermal patches being selected from the group consisting of reservoir patches, multilayer transdermal matrix systems, microreservoir patches, matrix patches, drug-containing adhesive patches, matrix patches combined with polymers, pressure-sensitive adhesive patches, sustained-release transdermal patches, liquid reservoir systems, microreservoir patches, Amco adhesive patches, and combinations thereof. This disclosure provides a pharmaceutical composition formulated as a topical patch, the topical patch being selected from the group consisting of a multilayer transdermal matrix system, a reservoir patch, a microreservoir patch, a matrix patch, a drug-containing adhesive patch, a pressure-sensitive adhesive patch, a sustained-release transdermal FDM liquid reservoir system, a microreservoir patch, an adhesive patch, a micro-administration patch, a matrix patch of an adhesive combined with a polymer, and combinations thereof. This disclosure also provides a pharmaceutical composition formulated as a transdermal preparation that can be administered in a dosage regimen selected from the group consisting of once daily, twice daily, three times daily, once every 1 to 8 hours, once every 1 to 24 hours, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every 8 to about 13 days, once every two weeks, and once every 15 to about 30 days. This disclosure provides a pharmaceutical composition formulated as a transdermal preparation that can be administered in a dosage regimen selected from the group consisting of once daily, twice daily, three times daily, once every 1 to 8 hours, once every 1 to 24 hours, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every 8 to about 13 days, once every two weeks, and once every 15 to about 30 days.This disclosure provides a pharmaceutical composition formulated as a topical preparation that can be administered in a dosage regimen selected from the group consisting of once a day, twice a day, three times a day, four times a day, five times a day, six times a day, once every 1 to 8 hours, once every 1 to 24 hours, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every 8 to about 13 days, once every two weeks, and once every 15 to about 30 days. This disclosure also provides a pharmaceutical composition formulated as a microneedle. This disclosure provides pharmaceutical compositions prepared by synthetic routes, comprising tetrahydrocannabinol (THC), cannabidiol (CBD), its free base, its salts, its isomers, its amorphous form, its polymorphs, its stereoisomers, its ion pairs, its coatings, its crystalline form, its cocrystals, its prodrugs, its analogues, its derivatives, its synthetic forms, its biosynthetic forms, its natural forms, its active metabolites, and combinations thereof. This disclosure concerns endometrial cancer, breast cancer, ovarian cancer, cervical cancer, fallopian tube cancer, testicular cancer, primary peritoneal cancer, colon cancer, colorectal cancer, small intestine cancer, anogenital squamous cell carcinoma, melanoma, renal cell carcinoma, lung cancer, non-small cell lung cancer, stomach cancer, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, salivary gland cancer, esophageal squamous cell carcinoma, stomach cancer, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, lung squamous cell carcinoma, lung squamous cell carcinoma, stomach cancer, bladder cancer, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, The present invention provides pharmaceutical compositions for the treatment and / or prevention and / or control of cancer in patients, selected from the group consisting of head and neck cancer, head and neck squamous cell carcinoma, prostate cancer, pancreatic cancer, mesothelioma, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, head and neck cancer, head and neck squamous cell carcinoma, prostate cancer, pancreatic cancer, mesothelioma, Merkel cell carcinoma, sarcoma, glioblastoma, GBM, hematological cancers, such as multiple myeloma, B-cell lymphoma, T-cell lymphoma, Hodgkin lymphoma / primary mediastinal B-cell lymphoma, and chronic myeloid leukemia.This disclosure provides pharmaceutical compositions prepared by synthetic routes for tetrahydrocannabinol (THC), cannabidiol (CBD), its free base, its salts, its isomers, its amorphous form, its polymorphs, its stereoisomers, its ion pairs, its coatings, its crystalline form, its cocrystal, its prodrugs, its analogues, its derivatives, its synthetic forms, its biosynthetic forms, its active metabolites, and combinations thereof. This disclosure provides pharmaceutical compositions prepared by synthetic routes for tetrahydrocannabinol (THC), cannabidiol (CBD), and their derivatives. This disclosure provides pharmaceutical compositions in which the activator is synthetically produced and has a purity of approximately 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.75%, or 100% (w / w) or higher before being added to the pharmaceutical composition. This disclosure provides pharmaceutical compositions that result in serum levels of an active agent selected from the group consisting of approximately 0.01 ng / mL, approximately 0.02 ng / mL, approximately 0.05 ng / mL, approximately 0.1 ng / mL, approximately 0.2 ng / mL, approximately 0.5 ng / mL, approximately 1 ng / mL, approximately 2 ng / mL, approximately 5 ng / mL, approximately 10 ng / mL, approximately 20 ng / mL, approximately 50 ng / mL, approximately 100 ng / mL, approximately 200 ng / mL, approximately 500 ng / mL, approximately 1 μg / mL, approximately 2 μg / mL, and approximately 5 μg / mL. This disclosure provides pharmaceutical compositions to be administered in combination with at least one further therapeutic agent selected from the group consisting of temozolomide, peptides, polypeptides, fusion proteins, nucleic acid molecules, small molecules, mimetic agents, synthetic drugs, inorganic molecules, organic molecules, biological therapies including chemotherapy, radiotherapy, hormone therapy, anti-angiogenic therapy, targeted therapy, and / or immunotherapy and surgery, and combinations thereof.

[0026] This disclosure provides a method for treating and / or preventing and / or controlling cancer in a patient, comprising the steps of selecting a patient in need of treatment and / or prevention and / or control of cancer, and applying topically a pharmaceutical composition disclosed herein. This disclosure provides methods for treating and / or preventing and / or controlling cancer in a patient, comprising the steps of: selecting a patient in need of treatment and / or prevention and / or control of cancer; and topically applying a pharmaceutical composition disclosed herein. This disclosure provides methods for treating and / or preventing and / or controlling cancer in a patient, including endometrial cancer, breast cancer, ovarian cancer, cervical cancer, fallopian tube cancer, testicular cancer, primary peritoneal cancer, colon cancer, colorectal cancer, small intestine cancer, anogenital squamous cell carcinoma, melanoma, renal cell carcinoma, lung cancer, non-small cell lung cancer, gastric cancer, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, salivary gland cancer, esophageal squamous cell carcinoma, gastric cancer, gallbladder cancer, liver cancer, thyroid cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, and esophageal cancer. The present disclosure provides a method for treating and / or preventing and / or controlling cancer in a patient, selected from the group consisting of head and neck cancer, head and neck squamous cell carcinoma, prostate cancer, pancreatic cancer, mesothelioma, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, head and neck cancer, head and neck squamous cell carcinoma, prostate cancer, pancreatic cancer, mesothelioma, Merkel cell carcinoma, sarcoma, glioblastoma, GBM, hematological cancers, e.g., multiple myeloma, B-cell lymphoma, T-cell lymphoma, Hodgkin lymphoma / primary mediastinal B-cell lymphoma, chronic myeloid leukemia. The present disclosure provides a method for treating and / or preventing and / or controlling cancer in a patient, wherein the cancer is glioblastoma or GBM. This disclosure provides a method for topical application of a transdermal pharmaceutical composition for the treatment and / or prevention and / or control of cancer in a patient, wherein the transdermal pharmaceutical composition is applied at intervals selected from the group consisting of once daily, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, and once every ten days. This disclosure further provides a method for delivering the active agent of the transdermal pharmaceutical composition at a constant delivery rate over a set period of time. This disclosure further provides a method for the treatment and / or prevention and / or control of cancer in a patient, wherein the absorption rate of the active agent of the transdermal pharmaceutical composition is delivered at a stable rate over a set period of time.This disclosure provides a method for treating and / or preventing and / or controlling cancer in a patient, further providing a method in which the serum blood level of the active agent of a transdermal pharmaceutical composition reaches a constant level over a period of time. This disclosure provides a method for treating and / or preventing and / or controlling cancer in a patient, further providing a method in which the temporal variation in the dose of the active agent of a transdermal pharmaceutical composition is reduced over a period of time. This disclosure provides a method for treating and / or preventing and / or controlling cancer in a patient, further providing a method in which the plasma concentration of the active agent of a transdermal pharmaceutical composition is brought to a therapeutic range over a period of time. This disclosure further provides a method for treating and / or preventing and / or controlling cancer in a patient, wherein the plasma concentration of the active agent of a transdermal pharmaceutical composition is brought to a therapeutic range of approximately 0.01 ng / mL to approximately 500 ng / mL. This disclosure provides a method for treating and / or preventing and / or controlling cancer in a patient, in which a continuous delivery system continuously delivers a pharmaceutical composition to a patient by intravenous or subcutaneous infusion. This disclosure provides a method for the treatment and / or prevention and / or control of cancer in a patient, wherein a continuous delivery system continuously delivers a pharmaceutical composition to a patient by subcutaneous injection. This disclosure provides a method for the treatment and / or prevention and / or control of cancer in a patient, wherein a pharmaceutical composition is continuously delivered to a patient by an infusion pump device. This disclosure provides a method for the treatment and / or prevention and / or control of cancer in a patient, wherein a pharmaceutical composition is continuously delivered to a patient by an outpatient / portable infusion pump that is attached to the patient and can use replaceable cartridges. This disclosure provides a method for the treatment and / or prevention and / or control of cancer in a patient, wherein a pharmaceutical composition is continuously delivered to a patient by a patch pump or micropump. This disclosure provides a method for treating and / or preventing and / or controlling cancer in a patient, comprising a pharmaceutical composition comprising a continuous delivery system comprising a pharmaceutical composition selected from the group consisting of liquid formulations, solid formulations, semi-solid formulations, emulsion formulations, nanoparticle formulations, matrix formulations, film formulations, patch formulations, formulations in an infusion pump, and / or combinations thereof.This disclosure provides a method for treating and / or preventing and / or controlling cancer in a patient, wherein the transdermal pharmaceutical composition is a formulation selected from the group consisting of creams, lotions, gels, oils, ointments, suppositories, sprays, foams, liniments, aerosols, cheek tablets and sublingual tablets, transdermal devices, and transdermal patches. This disclosure also provides a method for treating and / or preventing and / or controlling cancer in a patient, wherein the pharmaceutical composition is administered in combination with at least one further therapeutic agent selected from the group consisting of temozolomide, peptides, polypeptides, fusion proteins, nucleic acid molecules, small molecules, mimetic agents, synthetic drugs, inorganic molecules, organic molecules, chemotherapy, radiotherapy, hormone therapy, anti-angiogenic therapy, targeted therapy, and / or biological therapies including immunotherapy and surgery, and combinations thereof.

[0027] This disclosure provides for the use of the compositions of this disclosure for the manufacture of a medicament for the prevention and / or treatment of the indications described herein. In further embodiments, the present disclosure provides the use of the above-mentioned pharmaceutical composition in an amount effective for use in a pharmaceutical, most preferably for use in a subject, as a pharmaceutical for treating, for example, a disease or disorder described herein. In further embodiments, the disclosure provides the pharmaceutical compositions and at least one further therapeutic agent for pharmaceutical use, most preferably in a subject, in amounts effective for pharmacopoeia for the treatment of, for example, a disease or disorder related to a disease described herein. This disclosure provides a method for treating and / or preventing a disease or condition described herein in a patient, comprising the steps of: selecting a patient in need of treatment and / or prevention and / or control of the disease or condition described herein; and administering a therapeutically effective amount of the composition of this disclosure to the patient, thereby treating and / or preventing the disease in the patient. [Modes for carrying out the invention]

[0028] It should be understood that the present invention is not limited to the specific embodiments described, and such embodiments may, of course, be different. Since the scope of the present invention is limited only by the appended claims, it should also be understood that the terms used herein are for the sole purpose of describing specific embodiments and are not intended to limit them. The detailed description of the invention has been divided into various sections for the convenience of the reader, and any disclosure found in any section may be combined with other sections. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as that generally understood by a person ordinary in the art to which the invention pertains. Note that the singular forms “a,” “an,” and “the” used herein and in the appended claims include multiple references unless the context clearly indicates otherwise. Thus, for example, a reference to “compound” includes multiple compounds. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by an ordinary person skilled in the art to which this invention pertains. As used herein, the following terms have the following meanings:

[0029] As used herein, the term “pharmaceutically acceptable salt” includes acid addition salts or salts of free bases. The term “pharmaceutically acceptable salt” of an activator within that scope includes all possible isomers and mixtures thereof, as well as any pharmaceutically acceptable metabolites, bioprecursors and / or prodrugs, such as compounds having a different structural formula from the structural formula of the compounds disclosed herein, but which, when administered to a subject such as a mammal, particularly a human, are directly or indirectly converted to the compounds disclosed herein in vivo.

[0030] The terms “subject” and “patient” as used herein are interchangeable. As used herein, “patient” means an animal, preferably a mammal (e.g., non-primates (e.g., cattle, pigs, horses, cats, dogs, rats, etc.) and primates (e.g., monkeys and humans), most preferably humans). In some embodiments, the subject is a non-human animal such as livestock (e.g., horses, pigs, or cattle) or a pet (e.g., a dog or a cat). In certain embodiments, the subject is a human. In some embodiments, the subject is suffering from and / or susceptible to a disease, disorder, and / or condition (e.g., cancer). In some embodiments, the patient is a human being diagnosed with cancer. In some embodiments, the patient is a human being having one or more female reproductive organs. In some embodiments, the patient is a human female (e.g., a woman) diagnosed with gynecological cancer or breast cancer (e.g., ovarian cancer, fallopian tube cancer, peritoneal cancer, and breast cancer, etc.). As used in this specification, "patient population" or "group of subjects" refers to a group of patients or subjects.

[0031] As used herein, the term “drug” means any molecule, compound, methodology and / or substance for use in the prevention, treatment, management and / or diagnosis of a disease or condition. As used herein, the term “effective dose” means a dose sufficient to prevent the onset, recurrence or onset of a disease or condition and one or more of its symptoms; to enhance or improve the preventive effect of other treatments; to reduce the severity or duration of a disease or condition; to improve one or more of its symptoms; to prevent the progression of a disease or condition; to induce regression of a disease or condition; and / or to enhance or improve the therapeutic effect of other treatments.

[0032] As used herein, “pharmaceutically acceptable” means that it is approved by a federal or state government supervisory authority or is listed in the United States Pharmacopeia, the European Pharmacopeia, or any other generally recognized pharmacopoeia for use in animals, or more specifically, in humans. As used herein, the term “therapeutic agent” means any molecule, compound, and / or substance used to treat and / or manage a disease or disorder. As used herein, the terms “therapy” and “therapy” may mean any method, composition, and / or agent that can be used in the prevention, treatment, and / or management of a disease or condition, or one or more symptoms thereof. In certain embodiments, the terms “therapy” and “multiple therapies” mean small molecule therapies. As used herein, the terms “derivative” or “derivativeized” include, for example, chemical modifications of the compounds of the Disclosure, or compounds extracted from plant sources, or pharmaceutically acceptable salts thereof, or mixtures thereof. That is, a “derivative” may be a functional equivalent of the compounds of the Disclosure that can induce improved pharmacological activity in a given subject. The terms "composition" and "formulation" as used herein are interchangeable. As used herein, the term "transdermal delivery" refers to the delivery of a drug into the systemic circulation through the skin. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art in which this invention pertains. As used herein, the following terms have the following meanings:

[0033] Active ingredients As used herein, the term “active ingredient” means a drug, active ingredient compound, or other substance that produces some pharmacological, often beneficial, effect, or a composition or mixture thereof. When referring to a specific active ingredient, where appropriate, it includes that active ingredient and its pharmaceutically acceptable salts. This disclosure provides transdermal and / or topical formulations comprising, for example, one or more of the following activators: Cannabinoids are a group of 21-carbon-containing terpenophenol compounds produced by the cannabis species. Cannabinoids can also be produced synthetically. Hereinafter, the term “cannabinoid” refers to a diverse group of chemical compounds that act on cannabinoid receptors on cells that inhibit the release of neurotransmitters in the brain. These receptor proteins include endocannabinoids (naturally produced in the bodies of humans and animals), phytocannabinoids (found in cannabis and some other plants), and synthetic cannabinoids.

[0034] Activating agent The term “activator” means a drug, activator compound or other substance, or a composition or mixture thereof that provides several pharmacological, often beneficial effects. References to a specific activator shall, where appropriate, include the activator and its pharmaceutically acceptable salts. This disclosure provides transdermal formulations comprising, for example, one or more of the following activators: tetrahydrocannabinol (THC), cannabidiol (CBD), and combinations thereof. The term “activator” means a drug, activator compound or other substance, or a composition or mixture thereof that provides several pharmacological, often beneficial effects. References to a specific activator include, where appropriate, the activator and its pharmaceutically acceptable salts. This disclosure provides transdermal and / or topical formulations comprising, for example, one or more of the following activators: Cannabinoids are a group of 21-carbon-containing terpenophenol compounds produced by the cannabis species. Cannabinoids can also be produced synthetically. The term “cannabinoid” below means a diverse class of chemical compounds that act on cannabinoid receptors on cells that inhibit neurotransmitter release in the brain. These receptor proteins include endogenous cannabinoids (naturally produced in the body by humans and animals), phytocannabinoids (found in cannabis and several other plants), and synthetic cannabinoids. Lipophilic cannabinoids are generally classified as endogenous cannabinoids (most typically mammalian endogenous cannabinoids); phytocannabinoids of plant origin; and synthetic cannabinoids. These cannabinoids are also often classified into the following subclasses: cannabigerol (CBG); cannabichromene (CBC); cannabidiol (CBD; CBDL); tetrahydrocannabinol (THC); cannabinol (CBN); cannabicyclol (CBL); cannabiersoin (CBE); and cannabitriol (CBT). Cannabidiol IUPAC name 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol Chemical formula: C 21 H 30 O2 Molecular Weight: 314.46 Daltons The chemical structure is shown below, denoted by formula I.

[0035] [ka] Tetrahydrocannabinol (THC): IUPAC name (-)-(6aR,10aR)-6,6,9-trimethyl-3-pentyl- 6a,7,8,10a-tetrahydro-6H-benzo[c]chromen-1-ol Chemical formula: C 21 H 30 O2 Molecular weight: 314.47 daltons. The chemical structure is shown by the following formula II.

[0036] [ka] As used herein, the term "cannabis" refers to all pharmaceutically acceptable forms of cannabis and its derivatives, either alone or in combination, including, but not limited to, free bases, salts, isomers, amorphous forms, crystalline forms, cocrystals, solid solutions, prodrugs, analogs, derivatives, metabolites and their polymorphs, solid solutions and their coatings, stereoisomers and their ion pairs. Examples include free bases of cannabidiol, its salts, its isomers, its amorphous forms, its crystalline forms, cocrystals and their solid solutions, its prodrugs, its analogs, its derivatives or synthetic forms, its polymorphs and its stereoisomers and their ion pairs. The compound may be in the form of a pharmaceutically acceptable salt, such as an acid addition salt or a basic salt, or a solvate containing its hydrate. Suitable acid addition salts are formed from acids that form non-toxic salts, such as hydrochlorides, hydrobroms, hydroiodides, sulfates, hydrogen sulfates, nitrates, phosphates, hydrogen phosphates, acetates, maleates, fumarates, lactates, tartrates, citrates, glucons, succinates, saccharates, benzoates, methanesulfons, ethanesulfons, benzenesulfons, p-toluenesulfons, and pamoates. Suitable basic salts are formed from bases that form non-toxic salts, such as sodium, potassium, aluminum, calcium, magnesium, zinc, and diethanolamine salts.

[0037] As used herein, the term "cannabidiol" includes, but is not limited to, its free base, its salts, its isomers, its amorphous form, its crystalline form, its cocrystals, its prodrugs, its analogues, its derivatives and synthetic forms, its biosynthetic forms, its active metabolites, its solid solutions, its polymorphs, its stereoisomers, its powder form, its liquid form, its ion pairs, and solutions of cannabidiol in solvents such as methanol, either alone or in combination thereof.

[0038] As used herein, the term "THC" includes, but is not limited to, its free base, its salts, its isomers, its amorphous form, its crystalline form, its cocrystals, its prodrugs, its analogues, its derivatives, its synthetic forms, its biosynthetic forms, its active metabolites, its solid solutions, its powder form, its liquid form, its ion pairs, its polymorphs, its stereoisomers, and solutions of THC in solvents such as methanol and heptane, either alone or in combination thereof.

[0039] The synthetic cannabinoids used herein include at least the following: AM-087 is a cannabinoid agonist derivative of Δ8THC with a substituted 3-position side chain, and is a potent CB1 agonist and analgesic; AM-251 is an inverse agonist of the CB1 cannabinoid receptor, structurally similar to SR141716A (rimonabant), both of which are biarylpyrazole cannabinoid receptor antagonists, as are μ-opioid receptor antagonists; and methanandamide (AM-356) is a stable chiral analog of anandamide, and is a CB1 agonist. AM-374-palmitylsulfonylfluoride and AM-381-stearylsulfonyl fluoride act on cannabinoid receptors with a Ki of 17.9 nM and a Ki of 868 nM for CB2; AM-374-palmitylsulfonylfluoride and AM-381-stearylsulfonyl fluoride are also known as N-arachidonoylaminophenol and are active metabolites of paracetamol (acetaminophen). They are thought to induce analgesic effects through their activity on the endogenous cannabinoid system, the COX system, and the TRPV system present in the pain and thermoregulatory pathways; AM-411 is a cannabinoid agonist analgesic. AM-411 is a potent and highly selective CB1 complete agonist, producing effects similar to other cannabinoid agonists such as analgesia, sedation, and anxiolytics; AM661-1-(N-methyl-2-piperidine)methyl-2-methyl-3-(2-iodo)benzoylindole; JWH-018 (1-pentyl-3-(1-naphthoyl)indole) or AM-678 are analgesic chemicals belonging to the naphthoylindole family, acting as complete agonists for both CB1 and CB2 cannabinoid receptors. AM-679 acts as a moderately potent agonist against the cannabinoid receptor; AM-694 (1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole) acts as a potent and selective agonist against the cannabinoid receptor CB1; AM-735-3-bornyl-Δ8-THC is a mixed CB1 / CB2 agonist; AM-855 is an analgesic cannabinoid agonist against both CB1 and CB2, with moderate selectivity for CB1;AM881 is a chlorine-substituted stereoisomer of anandamide with Ki=5.3nM at CB1 and 95nM at CB2; AM-883 is an allyl-substituted stereoisomer of anandamide with Ki=9.9nM at CB1 and 226nM at CB2; AM-905 is an analgesic cannabinoid that acts as a potent and reasonably selective agonist for the CB1 cannabinoid receptor; AM-906 is a cannabinoid agonist and an analgesic that is a potent and selective agonist for the CB1 cannabinoid receptor; AM-919 is a potent analgesic for both CB1 and CB2 receptors. AM-926 is a pain-causing cannabinoid receptor agonist; it has moderate selectivity for CB1 and is a potent agonist for both CB1 and CB2 receptors; AM-938 is a cannabinoid receptor agonist analgesic that is a potent agonist for both CB1 and CB2 receptors, but moderately selective for CB2; AM-1116 is a dimethylated stereoisomer of anandamide; AM-1172 is an endogenous cannabinoid analog designed as a potent and selective AEA uptake inhibitor that is resistant to hydrolysis of FAAH; AM-12 AM-1221 is a potent and moderately selective agonist for cannabinoid receptor CB1; AM-1235 (1-(5-fluoropentyl)-3(naphthalene-1-oil)-6-nitroindole) is a potent and reasonably selective agonist for cannabinoid receptor CB1; AM-1241 (1-(methylpiperidine-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole) acts on cannabinoid receptor CB2 It is a potent and selective agonist, particularly effective in treating "atypical" pain such as hyperalgesia and allodynia in mammals, and also effective in treating amyotrophic lateral sclerosis in mammalian models; AM-1248 acts as a moderately potent agonist on cannabinoid receptors CB1 and CB2; AM-1710 shows 54-fold selectivity for CB1 and is a CB2-selective cannabilactone; AM-1714 acts as a reasonably selective agonist on peripheral cannabinoid receptor CB2 and possesses both analgesic and anti-allodynic effects;AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) acts as a potent but non-selective complete agonist of cannabinoid receptors; AM-2212 acts as a potent agonist of both CB1 and CB2; AM-2213 acts as a potent agonist of both CB1 and CB2; AM-2232 (1-(4-cyanobutyl)-3-(naphthalene-1-oil)indole) acts as a potent, non-selective agonist of cannabinoid receptors CB1 and CB2; AM-2233 acts as a potent agonist of cannabinoid receptors CB1 and It acts as a potent complete agonist for CB2 and has been found to completely replace THC in certain mammalian studies, with efficacy lower than JWH-018 and higher than WIN55,212-2; AM-2389 acts as a potent and reasonably selective agonist for the CB1 receptor; AM-3102 is an analog of oleoylethanolamide (an endogenous agonist for growth factor-activated receptor α (PPARα)) and acts as a weak cannabinoid agonist for CB1 and CB2; AM-4030 is a potent agonist for CB1 and CB2, but AM-4054 ​​is a moderately selective analgesic for CB1; AM-4113 is a potent but slow-acting agonist with moderate affinity for CB1 and selectivity for CB2; AM-6545 acts as a peripherally selective silent antagonist for CB1 and was developed for the treatment of obesity; JWH-007 is an analgesic that acts as a cannabinoid agonist at CB1 and CB2 receptors and has some selectivity for CB2; JWH-015 binds to CB2 almost 28 times more potently than CB1. It acts as a subtype-selective cannabinoid agonist and has been shown to have immunomodulatory effects, potentially useful in treating pain and inflammation; JWH018 is an analgesic that acts as a full agonist of CB1 and CB2 cannabinoid receptors, producing effects similar to THC; JWH-019 is a naphthoylindole family analgesic that acts as an agonist at CB1 and CB2 receptors and as a cannabinoid agonist at CB1 and CB2 receptors; JWH-030 is an analgesic that is a partial agonist of the CB1 receptor;JWH-047 is a potent and selective agonist of the CB2 receptor; JWH-048 is a potent and selective agonist of the CB2 receptor; JWH-051 is an analgesic with high affinity for the CB1 receptor but a stronger agonist for CB2; JWH-057 is a 1-deoxy analog of Δ8-THC with very high affinity for the CB2 receptor but also high affinity for the CB1 receptor; JWH-073 is a sedative that acts as a cannabinoid agonist on both the CB1 and CB2 receptors and is somewhat selective for the CB1 subtype. The following are somewhat selective for CB1 subtypes: JWH-081 is a sedative that acts as an agonist at both CB1 and CB2 receptors of cannabinoids; JWH-098 is a potent and fairly selective CB2 agonist; JWH-116 is a CB1 ligand; JWH-120 is a potent CB2 agonist with 173-fold selectivity; JWH-122 is a potent and fairly selective CB1 agonist; JWH-133 is a potent and selective CB2 receptor agonist; JWH-139 is 3-(1,1-dimethylpropyl)-6,6,9-trimethyl6a,7,10,10a-tetrahydro-6H-benzo[c]chromene; JWH-147 is a naphtopyrrole-based analgesic that acts as a cannabinoid agonist at both CB1 and CB2 receptors; JWH-148 JWH-149 is a moderately selective ligand for the CB2 receptor, with selectivity more than 8 times that of the CB1 subtype; JWH-161 is a potent and fairly selective CB2 agonist; JWH-161 is a CB1 ligand; JWH-164 is a potent cannabinoid agonist; JWH-166 is a potent and highly selective CB2 agonist; JWH-167 is a weak cannabinoid agonist of the phenylacetylindole family; JWH-171 is an analgesic that acts as a cannabinoid receptor agonist; JWH-175 is CB1 of (1-pentilindole-3-yl)naphthalene-1-ylmethane, 22 nM; JWH-176 is 1([(1E)-3-pentilindene-1-iridine]methyl)naphthalene; JWH-181 is a potent cannabinoid agonist;JWH-182 is a potent cannabinoid agonist with some selectivity for CB1; JWH-184 is 1-pentyl-1H-indole-3-yl(4-methyl-1-naphthyl)methane; JWH-185 is 1-pentyl-1H-indole-3-yl(4-methoxy-1-naphthyl)methane; JWH-192 is (1-(2-morpholine-4-ylethyl)indole-3-yl)-4-methylnaphthalene-1-ylmethane; JWH-193 is (1-(2-morpholine-4-ylethyl)indole- JWH-194 is 3-yl)-4-methylnaphthalene-1-ylmethanone; JWH-195 is (1-(2-morpholine-4-ylethyl)indole-3-yl)naphthalene-1-ylmethane; JWH-196 is 2-methyl-3-(1-naphthalenylmethyl)-1-pentyl-1H-indole; JWH-197 is 2-methyl-1-pentyl-1H-indole-3-(4-methoxy-1-naphthyl)methane JWH-198 is (1-(2-morpholine-4-ylethyl)indole-3-yl)-4-methoxynaphthalene-1-ylmethanone; JWH-199 is (1-(2-morpholine-4-ylethyl)indole-3-yl)-4-methoxynaphthalene-1-ylmethane; JWH-200 is an analgesic of the aminoalkylindole family that acts as a cannabinoid receptor agonist; JWH-203 is a cannabinoid agonist that acts with nearly equivalent affinity to CB1 and CB2 receptors. These are analgesics derived from the phenylacetylindole family; JWH-205 is 142-methyl-1-pentilindol-3-yl)-2-phenylethanone; JWH-210 is a naphthoylindole family analgesic that acts as a potent cannabinoid agonist at CB1 and CB2 receptors; JWH-213 is a potent and fairly selective CB2 agonist; JWH-229 is 1-methoxy-3-(1',1'-dimethylhexyl)-Δ8-THC, a dibenzopyrancannabinoid that is a potent CB2 agonist;JWH-234 is a CB2-selective cannabinoid agonist; JWH-250 is a phenylacetylindole family analgesic that acts as a cannabinoid agonist on CB1 and CB2 receptors; JWH-251 is (1-pentyl-3-(2-methylphenylacetyl)indole); JWH-258 is a potent, mildly selective CB1 agonist; JWH-302 is (1-pentyl-3-(3-methoxyphenylacetyl)indole); JWH-307 is a naphthoyl pyrrole family analgesic that acts as a cannabinoid agonist on CB1 and CB2 receptors; Acting as a cannabinoid agonist, it is somewhat selective for the CB2 subtype; JWH-350 is 11-nor-1-methoxy-3(1',1'-dimethylheptyl)-9α-hydroxyhexacannabinol, which has 33-fold selectivity for the CB2 receptor, high affinity for the CB2 receptor, and low affinity for the CB1 receptor; JWH-359 is a dibenzopyran-type cannabinoid that is a potent and selective CB2 receptor agonist; JWH-387 is 1-pentyl-(4-bromo-1-naphthoyl)indole, which acts as a potent cannabinoid agonist for both CB1 and CB2 receptors. These are analgesics of the naphthoylindole family; JWH-398 is an analgesic of the naphthoylindole family that acts as a potent cannabinoid agonist at CB1 and CB2 receptors, with a Ki of 2.3 nM at CB1 and 2.8 nM at CB2; JWH-424 is a potent and moderately selective CB2 agonist with a Ki of 5.44 nM at CB2 and 20.9 nM at CB1; HU-210 is a potent cannabinoid 100 to 800 times more potent than natural THC derived from cannabis, with a long duration of action and many of the same effects as natural THC; Adremic acid (Ajulemic acid (AB-III-56, HU-239, IP-751, CPL 7075, CT-3, Reznab) is a cannabinoid derivative of the non-psychoactive THC metabolite 11-nor-9-carboxy-THC, exhibiting useful analgesic and anti-inflammatory effects without inducing a subjective "high." The following are being developed as treatments for neuropathic pain and inflammatory diseases such as arthritis, as well as for rare life-threatening inflammatory diseases: HU-243 (AM-4056) is a cannabinoid that acts as a potent agonist at CB1 and CB2 receptors; HU-308 acts as a cannabinoid agonist and is highly selective for CB2 receptor subtypes.The following are analgesics that promote the proliferation of neural stem cells and protect both the liver and vascular tissue from oxidative stress through TNF-α inhibition; HU-331 is a quinone anti-carcinogenic compound synthesized from cannabidiol; HU-336 is an angiogenesis inhibitor that directly induces apoptosis of vascular endothelial cells and inhibits angiogenesis without altering the expression of pro-angiogenic cytokines and their receptors; HU-345 (cannabinol quinone) is a drug that can inhibit aortic ring angiogenesis more potently than its parent compound, cannabinol; CP47,497 or (C7)-CP47,497 are cannabinoid receptor agonists.

[0040] This disclosure also provides methods for the biosynthesis of cannabinoids, and methods for use in eukaryotic or prokaryotic expression systems for the production of biosynthetic enzymes that can be used in the manufacture of cannabinoids and cannabinoid analogs. Yeast, as well as eukaryotic and prokaryotic cells, is suitable for the cloning and expression of cannabinoid acid synthases, and includes, but is not limited to, Escherichia coli, yeast, and baculovirus hosts. Accordingly, this disclosure provides methods for producing biosynthetic cannabinoids, such as THC and / or CBD, using cannabinoid acid synthases, including, but not limited to, tetrahydrocannabinolate (THCA) synthase and cannabidiolic acid (CBDA) synthase. This disclosure further provides, for example, biosynthetic CBD alone or in combination with other activators, as disclosed herein and / or topical compositions.

[0041] In some embodiments, the transdermal and / or topical compositions described herein are for the prevention and / or treatment of cancer.

[0042] In certain embodiments described herein, a pharmaceutical composition or a transdermal or topical preparation may contain cannabidiol and / or THC—its free base, its salt, its isomer, its amorphous form, its crystalline form, its cocrystal, its prodrug, its analogue, its derivative, its synthetic form, its biosynthetic form, its active metabolite, its polymorph, its stereoisomer, its coating, its solid solution, its ion pair, or its solution in a solvent, either alone or in combination thereof. More preferably, transdermal and topical preparations may contain cannabidiol, its free base, its salt, its isomer, its amorphous form, its crystalline form, its cocrystal, its prodrug, its analogue, its derivative, its synthetic form, its biosynthetic form, its active metabolite, its polymorph, its ion pair, its stereoisomer, its coating, or a solution of cannabidiol in methanol, either alone or in combination thereof. More preferably, transdermal and topical formulations may contain THC, its free base, its salt, its isomers, its amorphous form, its crystalline form, its cocrystal, its prodrug, its analogue, its derivatives, its ion pairs, its synthetic form, its biosynthetic form, its active metabolite, its polymorph, its stereoisomer, its coating, or a solution of cannabidiol in methanol, either individually or in combination thereof.

[0043] As used herein, the term "cannabis" refers to all pharmaceutically acceptable forms of cannabis and its derivatives, either alone or in combination, including, but not limited to, free bases, salts, isomers, amorphous, crystalline, cocrystalline, solid solutions, prodrugs, analogs, derivatives, metabolites and their polymorphs, solid solutions and their coatings, stereoisomers and their ion pairs. Examples include free bases of cannabidiol, its salts, its isomers, its amorphous, its crystalline, its cocrystalline, its solid solutions, its prodrugs, its analogs, its derivatives or synthetic forms, its polymorphs, its stereoisomers and their ion pairs. The compound may be in the form of a pharmaceutically acceptable salt, such as an acid addition salt or basic salt, or a solvate containing its hydrate. Suitable acid addition salts are formed from acids that form non-toxic salts, such as hydrochlorides, hydrobroms, hydroiodides, sulfates, hydrogen sulfates, nitrates, phosphates, hydrogen phosphates, acetates, maleates, fumarates, lactates, tartrates, citrates, glucons, succinates, saccharates, benzoates, methanesulfons, ethanesulfons, benzenesulfons, p-toluenesulfons, and pamoates. Suitable basic salts are formed from bases that form non-toxic salts, such as sodium, potassium, aluminum, calcium, magnesium, zinc, and diethanolamine salts.

[0044] As used herein, “activators” may exist in the form of free bases or in the form of pharmaceutically acceptable salts. pharmaceutically acceptable salts forming parts of the present invention include, but are not limited to, alkali metal salts such as Li, Na, and K salts; alkaline earth metal salts such as Ca and Mg salts; salts of organic bases such as lysine, arginine, guanidine, diethanolamine, and choline; and salts of carboxylic acid moieties such as ammonium or substituted ammonium salts and aluminum salts. Salts may include, but are not limited to, acid addition salts such as sulfates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulfons, benzoates, salicylates, hydroxynaphthoates, benzenesulfons, ascorbicates, glycerophosphates, and ketoglutarates.

[0045] According to embodiments provided herein, the sustained delivery system includes formulations selected from the group consisting of liquid formulations, solid formulations, semi-solid formulations, emulsion formulations, nanoparticle formulations, matrix formulations, film formulations, patch formulations, infusion pumps, and / or combinations thereof. Embodiments are intended to be formulated to provide continuous sustained delivery in order to mitigate the peak and trough pharmacokinetic behavior associated with standard immediate-release oral delivery forms. Embodiments are intended to be formulated to provide administration routes selected from the group consisting of oral, buccal, mucosal, rectal, transdermal, topical, parenteral, and / or implantable, and / or combinations thereof.

[0046] As used herein, the term “activator” includes its free base, its salts, its isomers, its amorphous form, its crystalline form, its cocrystal, its prodrug, its analogues, its derivatives, its synthetic form, its biosynthetic form, its active metabolite, its polymorph, its stereoisomer, its coating, its solid solution, its ion pair, its racemic form, its natural extract, and its biosynthetic form, either alone or in combination. In some embodiments, the activator is highly purified. In some embodiments, the activator exists as a highly purified extract of the activator containing at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.75% (w / w) of the formulation. In one embodiment, the activator exists as a highly purified extract of the activator containing at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.75%, or 100% (w / w) of the dosage form. In one embodiment, the concentration of the activator is provided at about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.75%, or 100% (w / w) or more. In one embodiment, the activator is synthesized 100%. In one embodiment, the purity of the activator is about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.75%, or 100% (w / w) or higher. In one embodiment, the activator is produced synthetically, and its purity is about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.75%, or 100% (w / w) or higher. In one embodiment, the activator is a combination of activators, each of which is synthesized and whose purity may be independently about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.75%, or 100% (w / w) or higher.

[0047] In some embodiments, the dose of the activator is, for example, independently about 0.01, 0.1, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, or 45 mg / kg / day or more. In some embodiments, the activator is titrated from 5 to 20-25 mg / kg / day and optionally maintained for 10-15 days. In one embodiment, the dose of the activator is, for example, about 0.01, 0.1, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, or 400 micrograms / day or more. In one embodiment, the dose of the activator is, for example, about 0.01, 0.1, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, or 400 mg / day or more. In one embodiment, the dose of the activator is, for example, about 0.01, 0.1, 0.25, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 95, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, or 400 mg or more.In one exemplary embodiment, the dosage forms described herein are each independently expressed in amounts of approximately 0.01%, approximately 0.02%, approximately 0.05%, approximately 0.1%, approximately 0.2%, approximately 0.3%, approximately 0.4%, approximately 0.5%, approximately 0.6%, approximately 0.7%, approximately 0.8%, approximately 0.9%, approximately 1%, approximately 2%, approximately 3%, approximately 4%, approximately 5%, approximately 6%, approximately 7%, approximately 8%, approximately 9%, approximately 10%, approximately 11%, approximately 12%, approximately 13%, approximately 14%, approximately 15%, approximately 16%, approximately 17%, approximately 18%, approximately 19%, approximately 20%, approximately 21%, approximately 22%, approximately 23%, approximately 24%, and approximately 25% of the dosage form. It contains at concentrations of approximately 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, and 99.5%. In exemplary embodiments, the formulations described herein may independently contain activators at concentrations of about 0.1 to about 50%, about 1 to 20%, about 5% to 25%, about 10% to about 20%, or about 15% to about 18%, about 30% to about 70%, about 35% to about 65%, about 63.13%, and about 40% to about 64% w / w. In exemplary embodiments, in the exemplary formulations described herein, the activator is at a concentration of about 0.1% to about 50% by mass, about 1% to 75% by mass, preferably 2% to 30% by mass, and more preferably 5% to 20% by mass of the formulation.

[0048] This disclosure provides compositions and methods having the unique benefit of providing treatment for the condition described herein, which enables a patient or healthcare provider to titrate the dose to the most effective dose per patient, such as by adding dose-escalating patches. This disclosure provides compositions and methods having a unique function of immediately discontinuing drug administration simply by removing a patch. For example, a patient may be started at a dose that causes the development of an undesirable negative side effect. The patient or healthcare provider can control or discontinue the administration before it worsens (e.g., by removing the patch or titrating the administration with a lower-dose patch), and the duration of the undesirable experience can be dramatically reduced.

[0049] As used herein, the term “pharmaceutically acceptable salt” includes acid addition salts or addition salts of free bases. Within that scope, the term “pharmaceutically acceptable salt” of an activator includes all possible isomers and mixtures thereof, as well as any pharmaceutically acceptable metabolites, bioprecursors and / or prodrugs, such as compounds that, upon administration to a subject such as a mammal, particularly a human, have a different structural formula from one of the compounds described herein but are converted directly or indirectly in vivo to one of the compounds described herein. As used herein, the term "transdermal delivery" means the delivery of a drug into the systemic circulation via the skin.

[0050] Neoplasia (neoplasm) The present invention provides a method for treating neoplasms in patients requiring treatment of neoplasms, comprising administering to the patient a therapeutically effective amount of, for example, tetrahydrocannabinol (THC), cannabidiol (CBD), and combinations thereof, as exemplified herein, optionally in combination with, for example, a neoplasm treatment agent. As used herein, the term “neoplasm” also includes cancer, tumors, proliferative disorders, malignant tumors, and their metastases. Cancer is an abnormal proliferation of cells that grows in an uncontrolled manner and, in some cases, has a tendency to metastasize (spread). Cancer is not a single disease; it is a group of more than 100 different specific diseases. Cancer can involve any tissue in the body and can take many different forms in each area of ​​the body. Most cancers are named after the type of cell or organ in which they originate. Tumors can be malignant or benign. A benign tumor means that the tumor can grow but does not spread. A malignant tumor is malignant, meaning that it can grow and spread to other parts of the body. If cancer spreads (metastasizes), the new tumors have the same name as the original (primary) tumor. The frequency of a particular cancer can depend on sex. Skin cancer is the most common type of malignant tumor for both men and women, while the second most common type in men is prostate cancer, and in women it is breast cancer.

[0051] Examples of cancerous diseases include: head and neck (including salivary glands and oral cavity), gastrointestinal tract (including pharynx, esophagus, stomach, small intestine, large intestine, and anus), lungs, liver (including hepatocellular carcinoma, cholangiocarcinoma, and mixed tumors), extrahepatic bile ducts and gallbladder, pancreas (including tubular and acinar types), urogenital tract (including ovaries, fallopian tubes, guava, yolk sac tumors, seminomas, choriocarcinomas); sarcomas (including leiomyosarcoma, rhabdomyosarcoma, angiosarcoma, hemangioendothelioma, liposarcoma, chondosarcomas, fibrosarcoma, Ewing's sarcoma, malignant neurological tumors, alveolar soft tissue sarcoma, clear cell sarcoma, synovial sarcoma, and osteosarcoma); malignant tumors of the central nervous system (including astrocytoma, oligodendroglioma, glioblastoma, GBM, and medulloblastoma); and malignant tumors of the salivary glands (including adenoid cystic carcinoma, adenosquamous carcinoma, clear cell carcinoma, cystadenocarcinoma, and mucoepidermoid carcinoma). Mixed cancers (including hepatocellular carcinoma - cholangiocarcinoma, carcinosarcoma, adenoendocrine mixed carcinoma, and adenosquamous carcinoma); hepatocellular carcinoma; blastic malignancies (including hepatoblastoma, neuroblastoma, ganglioneuroblastoma, and nephroblastoma); renal cell carcinoma; neuroendocrine carcinoma; thyroid cancer (including papillary carcinoma, follicular carcinoma, medullary carcinoma, and anaplastic carcinoma); parathyroid carcinoma, pituitary carcinoma, adrenal carcinoma (including adrenocortical carcinoma and pheochromocytoma), and adenocarcinomas of combinations thereof. In some embodiments of this disclosure, cancers include endometrial cancer, breast cancer, ovarian cancer, cervical cancer, fallopian tube cancer, testicular cancer, primary peritoneal cancer, colorectal cancer, colon cancer, small intestine cancer, squamous cell carcinoma of the anal region, melanoma, renal cell carcinoma, lung cancer, non-small cell lung cancer, squamous cell carcinoma of the lung, gastric cancer, bladder cancer, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, head and neck cancer, head and neck squamous cell carcinoma, prostate cancer, pancreatic cancer, mesothelioma, Merkel cell carcinoma, sarcoma, glioblastoma, GBM, and hematological cancers such as multiple myeloma, B-cell lymphoma, T-cell lymphoma, Hodgkin lymphoma / primary mediastinal B-cell lymphoma, and chronic myeloid leukemia.

[0052] In some embodiments, cancers to be treated by the methods of the Disclosure further include sarcomas (e.g., myogenic sarcomas), leukemia, schwannomas, melanomas, and lymphomas. In some embodiments, patients or populations of patients treated with the combination therapy of the Disclosure include solid tumors. The methods of the Disclosure can be used to treat any type of cancer known in the Art. Non-limiting examples of cancers to be treated by the methods of the Disclosure include melanoma (e.g., metastatic melanoma), kidney cancer (e.g., clear cell carcinoma), prostate cancer (e.g., hormone-refractory adenocarcinoma of the prostate), pancreatic adenocarcinoma, breast cancer, colon cancer, lung cancer (e.g., non-small cell lung cancer), esophageal cancer, squamous cell carcinoma, liver cancer, ovarian cancer, cervical cancer, thyroid cancer, glioblastoma, GBM, glioma, leukemia, lymphoma, mesothelioma, sarcoma, and other neoplastic malignancies. Furthermore, the Invention also includes refractory or recurrent malignancies whose growth may be inhibited using the methods of the Invention. In some embodiments, cancers treated by the methods of the Disclosure include, for example, carcinomas, squamous cell carcinomas (e.g., cervix, eyelids, conjunctiva, vagina, lungs, oral cavity, skin, bladder, head and neck, tongue, larynx, and esophagus), and adenocarcinomas (e.g., prostate, small intestine, endometrium, cervix, large intestine, lungs, pancreas, esophagus, rectum, uterus, stomach, mammary glands, and ovaries). In some embodiments, cancers treated by the methods of the Disclosure further include sarcomas (e.g., myogenic sarcomas), leukemia, neuromas, melanomas, and lymphomas.

[0053] In some embodiments, the patient or population of patients treated with the combination therapy of the Disclosure has solid tumors. In some embodiments, solid tumors are melanoma, renal cell carcinoma, lung cancer, bladder cancer, breast cancer, cervical cancer, colon cancer, gallbladder cancer, laryngeal cancer, liver cancer, thyroid cancer, gastric cancer, salivary gland cancer, prostate cancer, pancreatic cancer, mesothelioma, sarcoma, or Merkel cell carcinoma. In some embodiments, the patient or population of patients treated with the combination therapy of the Disclosure has hematological cancers. In some embodiments, the patient has hematological cancers such as diffuse large B-cell lymphoma ("DLBCL"), Hodgkin lymphoma ("HL"), non-Hodgkin lymphoma ("NHL"), follicular lymphoma ("FL"), acute myeloid leukemia ("AML"), or multiple myeloma ("MM").

[0054] neoplastic therapy Any therapy (e.g., therapeutic or prophylactic agent) that is useful, has been used, is currently used, or may be used for the prevention, treatment, and / or management of neoplasms may be used by means of the methods, compositions, and combinations of the present invention to prevent, treat, and / or manage patients with neoplasms and / or cancer. Furthermore, neoplastic and / or cancer monitoring can be used in combination with any cancer treatment according to the present invention. Examples of therapeutic agents (e.g., therapeutic or prophylactic agents) include, but are not limited to, peptides, polypeptides, fusion proteins, nucleic acid molecules, small molecules, mimetic agents, synthetic drugs, inorganic molecules, and organic molecules. Non-limiting examples of cancer therapies include biological therapies, including chemotherapy, radiotherapy, hormone therapy, anti-angiogenic therapy, targeted therapy, and / or immunotherapy and surgery. In certain embodiments, a prophylactic and / or therapeutically effective regimen includes the administration of a combination of therapies.

[0055] Examples of new plasty agents or therapies include, but are not limited to, asibicin; acralubicin; acodazole hydrochloride; acronin; adzeresin; aldesleukin; altretamine; ambomycin; amethantrone acetate; aminoglutethimide; amsacrin; anastrozole; anthracycline; anthramycin; asparaginase; asperlin; azacitidine (vidaza); azetepa; azotomycin; batimastat; benzodepa; bicalutamide; hydrochloride Bisantrene; Bisnafide dimesylate; Bisphosphonates (e.g., pamidronate (Aredria), sodium clodronate (Bonfos), zoledronic acid (Zometa), alendronate (Fosamax), etidronate, ibandronate, simadronate, risedronate, and tildronate); Bizeresin; Bleomycin sulfate; Brekinal sodium; Bropyrimine; Busulfan; Kakutinomycin; Carsterone; Calasemide; Carbethymer; Carboplatin; Carmustine; Carrubicin hydrochloride; Carzeresin; Sedefingol; Chlorambucil; Cirolmycin; Cisplatin; Cladribine; Crisnator mesylate (Crizun mesylate); Cyclophosphamide; Cytarabine (Ara-C); Dacarbazine; Dactinomycin; Daunorubicin hydrochloride; Decitabine (Dacogen); Demethylating agents, Dexormaplatin; Dezaguanine; Dezaguanine mesylate; Cyclophosphamide; Eflornithine hydrochloride; EphA2 inhibitors; Elsamitrusine; Enloplatin; Empromate; Epipropyl Zin; Epirubicin hydrochloride; Epirubicin hydrochloride; Elbrozole; Fadrozol hydrochloride; Estramustine; Estramustine sodium phosphate; Etanidazole; Etoposide; Etoposide phosphate; Fludarabine phosphate; Fluorouracil; Fluorocitabine; Ifosfamide; Ilmosine; Imatinib mesylate (Gleevec, Glivec); Interleukin II (including recombinant interleukin II or rIL2), Interferon α-2a; Interferon α-2b; Interferon α-n1; Interferon α-n3; Interferon β-I a; Interferon γ-I b; Iproplatin; Irinotecan hydrochloride; Lanreotide acetate; Lenalidomide (Rebrimid); Letrozole;Leuprolide acetate; Liriosol hydrochloride; Lometrexol sodium; Lomustine; Rosoxantrone hydrochloride; Masopropyl; Maytansine; Mechloretamine hydrochloride; Anti-CD2 antibodies (e.g., cyprizumab (MedImmune Inc. WO 02 / 098370, the whole thereof is incorporated herein by reference)); Megestrol acetate; Melengestrol acetate; Melphalan; Menogalil; Mercaptopurine; Methotrexate; Methotrexate sodium; Metoprin; Metredepa; Mifepristone; Mitindomide; Mitocalcin; Mitochromin; Mitogiline; Mitomarcin; Mitomycin; Mitospar; Mitotan; Mitoxantrone hydrochloride; Mycophenolic acid; Nocodazole; Nogaramycin; Ormaplatin; Oxaliplatin; Oxythran; Paclitaxel; Pegaspagaze; Periomycin; Pentamustine; Peplomycin sulfate; Perphosphamide; Pipobroman; Piposulfan; Piroxantrone hydrochloride; Plicamycin; Promestan; Porfimer sodium; Porphyromycin; Prednimustine; Procarbazine hydrochloride; Puromycin; Puromycin hydrochloride; Pyrazofrine; Ribopurine; Logretimide; RU486; Safingol; Safingol hydrochloride; Semustine; Simtrazene; Sperfosate sodium; Sparsomycin; Spirogermanium hydrochloride; Spiromustine; Spiroplatin Examples include streptonigrin, streptozocin, throphenur, tarisomycin, tecogalan sodium, tegafur, teloxantrone hydrochloride, temoporfin, teniposide, teroxylone, testolactone, thiamiprine, thioguanine, thiotepa, thiazophrine, tirapazamine, toremifene citrate, trestrone acetate, trisilibine phosphate, trimethrexate, trimethrexate glucuronate, triptrelin, tubulozol hydrochloride, uracil mustard, uredepa, bapreotide, verteporfin, vinblastine sulfate, vincristine sulfate, vindesine, vindesine sulfate, vinpiridine sulfate, vinylinate sulfate, vinoleurbin sulfate, violerbin tartrate, vinrosidine sulfate, vinzolidine sulfate, volozol, zeniplatin, dinostatin, and zolubicin hydrochloride.

[0056] Other examples of cancer treatments include, but are not limited to, the following: 20-Epi-1,25-Dihydroxyvitamin D3; 5-Ethinyluracil; Abiraterone; Acralubicin; Acylflubene; Adesipenolic acid; Adzelesin; Aldesleukin; ALL-TK antagonist; Altretamine; Ambamustine; Amidox; Amifostine; Aminolevulinic acid; Amrubicin; Amsacrine; Anagrelide; Anastrozole; Andrographolide; Angiogenesis inhibitor; Antagonist D; Antagonist G; Antarelix; Anti-dorsal morphogenesis protein-1; Anti-androgen, prostate cancer; Anti-estrogen; Anti-neoplaston; Antisense oligonucleotide; Aphydicolinglycinate; Apoptosis gene regulator Apoptosis regulators; aprinic acid; ara-CDP-DL-PTBA; arginine deaminase; asracrin; atamestan; atrimustin; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; valanol; batimastat; BCR / ABL antagonists; benzochlorin; benzoyl staurosporine; β-lactam derivatives; β-arrestin; betacumycin B; betulinic acid; bFGF inhibitors; bicalutamide; bisanthren; bisaziridinylspermine; bisnafide; bistratin A; bizuresin; breflate; bropyrimine; budotitan; butionine sulfoximine; calcipotriol; carphostin C; camptothecin derivatives; canariapox IL-2; capecitabine; carboxamide-aminotriazole; carboxyamide triazole; CaRest M3; CARN700; cartilage-derived inhibitors; carzeresin; casein kinase inhibitors (ICOS); castanospermine; cecropine B; cetrorelix; chlorine; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomiphene analogs; clotrimazole; colismycin A; colismycin B; combretastatin A4; combretastatin analogs; conagenin; crambecidin 816; crisnator; cryptophycin 8; cryptophycin A derivatives; clasin A; cyclopentanetraquinone; cycloplatam; cypemycin; cytarabine ocosphate; cytolytic factors; cytostatin; dacliximab; decitabine;Dehydrodemnin B; Deslorerin; Dexamethasone; Dexphosphamide; Dexrazoxane; Dexverapamil; Diadicon; Didemnin B; Zidox; Diethylnorspermine; Dihydro-5-azacitidine; Dihydrotaxol, Dioxamycin; Diphenylspiromustine; Docetaxel; Docosanol; Dracetron; Doxifluridine; Doroxifen; Dronabinol; Duocalmycin SA; Ebselen; Ecomustine; Edelfosine; Edrecolomab; Eflomitin; Elemen; Emiteflu; Epirubicin; Epristeride; Estramustine analog; Estrogen agonist; Estrogen antagonist; Etanidazole; Etoposide phosphate; Exemestane; Fadrozol; Fazarabine Fenretinide; Filgrastim; Finasteride; Flavopyridol; Frezelastine; Fluasterone; Fludarabine; Fluorodaunornicin hydrochloride; Forphenimex; Formestan; Fostoriesin; Fotemustine; Gadolinium texaphylline; Gallium nitrate; Gallocitabine; Ganirelix; Gelatinase inhibitors; Gemcitabine; Glutathione inhibitors; HMG CoA reductase inhibitors (e.g., atorvastatin, cerivastatin, fluvastatin, Rescol, Lupitor, lovastatin, rosuvastatin, and simvastatin); hepsulfame; helegulin; hexamethylene bisacetamide; hypericin; ibandronate; idarubicin; idoxifen; idramanthon; irmofosin; ilomastat; imidazoacridone; imiquimod; immunostimulatory peptides; insulin-like growth factor-1 receptor inhibitors; interferon agonists; interferon; interleukin; iobenguan; iododoxorubicin; ipomeanol, 4-iroplact; ilsogladine; isobengazole; isohomohalichondrin B; itasetron; jasplakinol; kahalide F; lamellarin-N triacetate; lanreotide; lenamycin; lenograstim Lentinan sulfate; leptolstatin; letrozole; leukemia inhibitor; leukocyte alpha interferon; leuprolide + estrogen + progesterone; leuprorelin; levamisol;LFA-3TIP (Biogen, Cambridge, Mass. International Publication No. 93 / 0686 and U.S. Patent No. 6,162,432); liarozole; linear polyamine analog; lipophilic disaccharide peptide; lipophilic platinum compound; lysocrineamide 7; lovaplatin; rombricin; lometrexol; ronidamine; losoxantrone; lovastatin; loxoribine; lulutotecan; lutetium texaphylline; lysophylline; soluble peptide; mytansine; mannostatin A. marimastat; masopropyl; maspine; matrilysin inhibitor; matrix Smetaloproteinase inhibitors; Menogalil; Melbaron; Meterelin; Methioninase; Metoclopramide; MIF inhibitors; Mifepristone; Miltefosine; Millimostim; Mimatch double-stranded RNA; Mitoguazone; Mitractol; Mitomycin analogs; Mitonafide; Mitotoxin fibroblast growth factor-saporin; Mitoxantrone; Mofalotene; Morglamostim; Monoclonal antibodies, human chorionic gonadotrophins; Monophosphoryl lipid A + Mycobacterium cell wall SK; Mopidamole; Multidrug resistance gene inhibitors; Treatment based on multitumor suppressors; Mustard anticancer agent; Mycaperoxide B; Mycobacterial cell wall extract; Myriapolon; N-acetyldinaline; N-substituted benzamide; Nafarelin; Nagreschip; Naloxone + pentazocine; Napavin; Naphtharpin; Naltgrastim; Nedaplatin; Nemorubicin; Neridronic acid; Neutral endopeptidase; Niltamide; Nisamycin; Nitric oxide regulator; Nitroxide antioxidant; Nitrulline; O6-benzylguanine; Octreotide; Oxenon; Oligonucleotide; Onapristone; Oracin; Oral cytokine inducer; Ormaplatin; Osateron; Oxaliplatin; Oxaunomycin; Paclitaxel; Paclitaxel analogues; Paclitaxel derivatives Paraamine; palmitoyl rhizoxine; pamidronic acid; panaxitriol; panomiphene; parabactin; pazeriptin; pegaspargase; perdesin; pentosan sodium polysulfate; pentostatin; pentrozole; perflubron perphosphamide; periryl alcohol; phenazinomycin; phenyl acetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride;Pirarubicin; pyritrexime; placetin A; placetin B; plasminogen activator inhibitors; platinum complexes; platinum compounds; platinum-triamine complexes; porfimer sodium; porphyromycin; prednisone; propylbis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immunomodulators; protein kinase C inhibitors; protein kinase C inhibitors, microalgae; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurin; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene; raf antagonists; lartitrexed; ramosetron; ras farnesyltransferase inhibitors; ras inhibitors; ras-GAP inhibitors; reteriptin demethylation; rhenium Re 186 etidronate Rhizoxin; Ribozyme; RII Retinamide; Logretimide; Rohitzkin; Lomultide; Lokinimex; Rubiginon B1; Ruboxil; Safingol; Santopine; SarCNU; Sarcophytol A; Salglamostim; Sdi 1 mimetic; Semustin; Aging-derived inhibitors; Sense oligonucleotides; Signaling inhibitors; Signaling modulators; Gamma-secretase inhibitors, single-chain antigen-binding proteins; Schizofran; Sobuzoxane; Sodium bolocaptate; Sodium phenylacetate; Sorbelol; Somatomedin-binding protein; Sonarmin; Superphostic acid; Spicamycin D; Spiromustin; Suprenopentin Sponge statin 1; squalamine; stem cell inhibitors; stem cell division inhibitors; stipiamide; stromelysin inhibitors; sulfinosine; hyperactive vasoactive intestinal peptide antagonists; sladista; suramin; swinesonin; synthetic glycosaminoglycans; talimustin; 5-fluorouracil; leucovorin; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; telrapyrilium telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; talibrastin; thiocholalin; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonists; thymotrinan; thyroid-stimulating hormone; tin ethylethiopurine; tirapazamine; titanosenbicloride;Topcentin; toremifene; tortiv stem cell factor; translation inhibitors; tretinoin; triacetyluridine; trisilibine; trimethrexate; triptrelin; tropisetron; turosteride; tyrosine kinase inhibitors; tilphostine; UBC inhibitor ubenimex; urogenital sinus-derived growth inhibitors; urokinase receptor antagonists; vapreotide; variolin B; vector systems, erythrocyte gene therapy; thalidomide; veraresol; veramine; verdin; verteporfin; vinorelbine; vinxaltin; anti-integrin antibodies (e.g., anti-integrin A, sub, V, B, sub, 3 antibodies, etc.); borozol; zanoterone; zeniplatin; zirascorb; and dinostatin stimulamer.

[0057] A non-exclusive list of compounds that can be used to target neoplasms and / or cancer includes: inhibitors of interleukin-3 receptor (IL-3R) and CD123 (including peptides, peptide complexes, antibodies, antibody complexes, antibody fragments, and antibody fragment complexes that target IL-3R or CD123); cantharidin, norcantharidin, and their analogues and derivatives; Notch pathway inhibitors, including γ-secretase inhibitors; Sonic Hedgehog / Smoothund pathway inhibitors, including cyclopamine and its analogues; antibodies against CD96; certain NF-κB / proteasome inhibitors, including parthenolide and its analogues; certain triterpenes, including cerastrol; certain mTOR inhibitors; compounds and antibodies that target urokinase receptors; synefungins; certain inosine monophosphate dehydrogenase (IMPDH) inhibitors; PP AR-α and PP AR-γ agonists and antagonists (pioglitazone, tesaslitazar, mulaglitazar, periglitazar, lobeglitazone, paraglitazone, lagaglitazar, rodiglitazone, falglitazar, sodelglitazar, reglitazar, nabeglitazar, oxeglitazar, metaglidacene, netoglitazone, dalglitazone, englitazone, thiazolidinedione, alleglitazar, edaglitazone) Examples include: riboglitazone, troglitazone, imiglitazar, and sipoglitazar; telomerase inhibitors; antibodies against EpCAM (ESA); GSK-3β agonists and antagonists (including lithium, 6-bromoinirubin-3'-oxime (BIO), and TDZD8); Wnt pathway inhibitors, such as antibodies against Frizzled, or small molecules that inhibit Frizzled / Frizzled or β-catenin; anti-C133 antibodies; anti-C44 antibodies; antibodies against IL-4; specific differentiation agents such as versnarinone; compounds targeting C33; compounds targeting lactoadherin; small molecules or antibodies targeting CXCR4 or SDF-1; small molecules or antibodies targeting multidrug resistance pumps; survivin inhibitors; XIAP inhibitors; small molecules targeting Bcl-2; antibodies against CLL-1; and furin inhibitors (such as cucurbitacin).

[0058] A further, non-limiting list of compounds that may also be used to target cancer and / or cancer cells includes the following small molecules known in the art, including i) antibodies, antibody fragments, and proteins that are either naked or conjugated to therapeutic portions that target specific cell surface targets on cancer cells, or ii) those that can be further optimized (e.g., chemically) or identified by cancer cell-based screening (e.g., determining whether a compound impairs the proliferation or viability of cancer cells by standard methods): Rex 1(Zfp42), CTGF, Activin A, Wnt, FGF-2, HIF-1, AP-2γ, Bmi-1, Nucleostemin, Hiwi, Moz-TIF2, Nanog, β-Arrestin-2, Oct-4, Sox2, Stella, GDF3, RUNX3, EBAF, TDGF-1, Nodal, ZFPY, PTNE, Evi-1, Pax3, Mcl-1, c-kit, Lex-1, Zfx, Lactoadherin, Aldehyde Dehydrogenase, BCRP, Telomerase, CD133, Bcl-2, CD26, Gremlin, and FoxC2.

[0059] In some embodiments, the therapy(s) are immunomodulators. Non-limiting examples of immunomodulators include cytokines, peptide mimes, and protein agents such as antibodies (e.g., human, humanized, chimeric, monoclonal, polyclonal, Fvs, scFvs, Fab or F(ab)2 fragments or epitope-binding fragments), nucleic acid molecules (e.g., antisense nucleic acid molecules and triple helices), small molecules, organic compounds, and inorganic compounds. Examples of immunomodulators include, but are not limited to, methotrexate, leflunomide, cyclophosphamide, cytoxane, Imuran, cyclosporine A, minocycline, azathioprine, antimicrobial agents (e.g., FK506 (tacrolimus)), methylprednisolone (MP), corticosteroids, steroids, mycophenolate mofetil, rapamycin (sirolimus), mizoribine, deoxysperguarine, brequinal, malononitrilamide (e.g., leflunamide), T receptor modulators, cytokine receptor modulators, and modulator mast cell modulators. Other examples of immunomodulators can be found, for example, in paragraphs 259-275 of U.S. Patent Application Publication 2005 / 0002934 A1, which is incorporated in its entirety herein by reference. In one embodiment, the immunomodulator is a chemotherapeutic agent. In other embodiments, the immunomodulator is an immunomodulator other than a chemotherapeutic agent. In some embodiments, the treatment used according to the present invention is not an immunomodulator.

[0060] In some embodiments, the therapy(s) are anti-angiogenic agents. Non-limiting examples of anti-angiogenic agents include proteins, polypeptides, peptides, fusion proteins, antibodies (e.g., human, humanized, chimeric, monoclonal, polyclonal, Fvs, scFvs, Fab fragments, F(ab2 fragments, and their antigen-binding fragments), e.g., antibodies that specifically bind to TNF-α), nucleic acid molecules (e.g., antisense molecules or triple helices), organic molecules, inorganic molecules, and small molecules that reduce or inhibit angiogenesis.

[0061] In certain embodiments, the therapy(s) may include alkylating agents, nitrosourea, antimetabolites, and anthracyclines, topoisomerase II inhibitors, or mitotic inhibitors. Examples of alkylating agents include, but are not limited to, busulfan, cisplatin, carboplatin, chlorambucil, cyclophosphamide, ifosfamide, decarbazine, mechloretamine, mephalen, and temozolomide. Examples of nitrosourea include, but are not limited to, carmustine (BCNU) and lomustine (CCNU). Examples of antimetabolites include, but are not limited to, 5-fluorouracil, capecitabine, methotrexate, gemcitabine, cytarabine, and fludarabine. Examples of anthracyclines include, but are not limited to, daunorubicin, doxorubicin, epirubicin, idarubicin, and mitoxantrone. Examples of topoisomerase II inhibitors include, but are not limited to, topotecan, irinotecan, etoposide (VP-16), and teniposide. Examples of mitotic inhibitors include, but are not limited to, taxanes (paclitaxel, docetaxel) and vinca alkaloids (vinblastine, vincristine, and vinorelbine). In some embodiments of the present invention, the treatment(s) include the administration of cantharidin or its analogues. The present invention includes the use of agents that target cancer cells. In certain embodiments, the agent acts alone. In other embodiments, the agent is attached directly or indirectly to other therapeutic sites.Non-limiting examples of therapeutic components include, but are not limited to, alkylating agents, antimetabolites, plant alkaloids, cytotoxic agents, chemopterants (e.g., steroids, cytosine arabinoside, fluorouracil, methotrexate, aminopterin, mitomycin C, demecolsin, etoposide, mitramycin, calicheamicin, CC-1065, chlorambucil, or melphalan), radionuclides, therapeutic enzymes, cytokines, toxins (including plant-derived toxins, fungal-derived toxins, bacterial-derived toxins (e.g., deglycosylated lysine A chain, ribosome-inactivating proteins, α-sarcin, aspergiline, restiltocin, ribonuclease, diphtheria toxin, Pseudomonas exotoxin, bacterial endotoxins, or the lipid A portion of bacterial endotoxins)), growth regulators, and RNases. In some embodiments, the active ingredient used is a marker, such as an active ingredient that binds to an antigen on cancer cells. In one embodiment, the drug binds to an antigen that is expressed at a higher level on cancer cells than on normal cells. In another embodiment, the drug specifically binds to cancer cell antigens that are not on normal cells. In yet another embodiment, the drug binds to a marker on cancer cells. In one embodiment, the drug that binds to the marker on cancer cells is an antibody, or an antibody conjugated to a therapeutic portion, or an antibody fragment conjugated to a therapeutic portion.

[0062] For example, in certain embodiments, the drug specifically binds to the IL-3 receptor (IL-3R). In some embodiments, the drug that binds to IL-3R is an IL-3R-specific antibody or antibody fragment. In some embodiments, the antibody or antibody fragment is conjugated to a therapeutic moiety (e.g., a chemotherapeutic agent, a plant, fungal or bacterial toxin, or a radionuclide) either chemically or via recombinant technology using a conjugate that induces a cell death response. In certain embodiments, the antibody, antibody complex, antibody fragment, or antibody fragment conjugate binds to the α subunit of IL-3R (i.e., the CD 123 antigen). In other embodiments, the antibody, antibody complex, antibody fragment, or antibody fragment complex binds to IL-3R containing both the α and beta subunits. Methods for preparing antibodies against IL-3R and mimics of antibodies against IL-3R are described in U.S. Patent No. 6,733,743B2, which is incorporated herein by reference in its entirety.

[0063] In other embodiments, the drug that binds to a marker on cancer cells is a ligand. In some embodiments, the ligand is a cytokine that binds to a cytokine receptor on cancer cells. In certain embodiments, the ligand is interleukin-3 (IL-3), which may be conjugated to a therapeutic moiety containing a chemotherapeutic agent, a plant-derived toxin, a fungal toxin, or a bacterial toxin, or a radionuclide. The IL-3 conjugated prophylactic and / or therapeutic therapy or regimen may be in the form of a recombinant fusion protein in embodiments where the conjugate is a toxin and the toxin is a protein such as diphtheria toxin.

[0064] In certain embodiments, an antibody or fragment thereof that binds to a marker on cancer cells is substantially non-immunogenic in the treated subject. Methods for obtaining a non-immunogenic antibody include, but are not limited to, chimerizing the antibody, humanizing the antibody, and isolating the antibody from the same species as the treated subject. The antibody or fragment thereof that binds to the marker in cancer cells may be produced using techniques known in the art.

[0065] In some embodiments, the therapy includes the use of X-rays, gamma rays, and other radiation sources to destroy cancer cells and / or cancer cells. In certain embodiments, radiotherapy is administered as external beam radiation or remote therapy, with the radiation directed from a remote source. In other embodiments, radiotherapy is administered as internal therapy or close-range radiation therapy, where the radiation source is positioned inside the body in close proximity to the cancer cells, cancer cells, and / or tumor mass.

[0066] In some embodiments, the treatment used is a growth-based treatment. Non-limiting examples of such treatments include the chemotherapy and radiotherapy described above.

[0067] The currently available therapies, their dosages, routes of administration, and recommended uses are publicly known in the art and are described in literature such as the Physician's Desk Reference (60th edition, 2006).

[0068] When two prophylactic and / or therapeutically effective regimens are administered simultaneously to a subject, the term “simultaneously” is not limited to the administration of the cancer drugs at exactly the same time, but rather means that they are administered to the subject in an order and time interval such that they can act together (e.g., synergistically to provide an increased benefit than if they were administered in any other way). For example, cancer drugs may be administered simultaneously or sequentially in any order at different times, but if not administered simultaneously, they should be administered at sufficiently close intervals to provide the desired therapeutic effect, preferably in a synergistic manner. Combination cancer drugs may be administered separately in any appropriate form and by any preferred route. If the components of the combination cancer drugs are not administered in the same pharmaceutical composition, it is understood that they may be administered in any order to the subject requiring them. For example, a first prophylactic and / or therapeutically effective regimen may be administered to a subject in need of it before (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks prior), simultaneously with, or after (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks prior) the administration of a second cancer drug. In various embodiments, cancer drugs are administered at intervals of 1 minute, 10 minutes, 30 minutes, less than 1 hour, 1 hour, 1 to 2 hours, 2 to 3 hours, 3 to 4 hours, 4 to 5 hours, 5 to 6 hours, 6 to 7 hours, 7 to 8 hours, 8 to 9 hours, 9 to 10 hours, 10 to 11 hours, 11 to 12 hours, 24 hours or less, or 48 hours or less. In one embodiment, cancer drugs are administered within the same hospital visit. In other embodiments, concomitant cancer drugs are administered at intervals of 1 minute to 24 hours.

[0069] In certain embodiments, the combination therapies have the same mechanism of action. In other specific embodiments, the combination therapies each have a different mechanism of action.

[0070] Further activators As used herein, the term “combined administration” with respect to compounds, therapeutic agents, or combinations of known drugs with the present invention means the administration of a drug and one or more compounds at a time such that both the known drug and / or combination produce a therapeutic effect. In some cases, this therapeutic effect will be synergistic. Such concurrent administration may include simultaneous (i.e., concurrent), pre-, or post-administration of the drugs with respect to the administration of the compositions and / or combinations of the present invention. Those skilled in the art will not have difficulty determining the appropriate timing, order, and dosage of administration for specific drugs of the present invention. Furthermore, the active ingredient(s) may, where applicable, exist either in the form of a single substantially optically pure enantiomer or as a mixture of the enantiomer or its polymorphs.

[0071] Activating agents include the following therapeutic classes: anti-adrenergic drugs; corticosteroids; corticosteroids; aldosterone antagonists; amino acids; anabolic agents; analgesics; anesthetics; antispasmodics; anti-acne drugs; anti-adrenergic drugs; anti-allergic drugs; anti-amoebic drugs; anti-anemia drugs; anti-angina drugs; anti-arthritis drugs; anti-asthma drugs; anti-atherosclerotic drugs; antibacterial drugs; anticholinergic drugs; anticoagulants; anticonvulsants; antidepressants; antidiabetic drugs; antidiarrheal drugs; antidiuretics; antiemetic drugs; antiepileptic drugs; antifibrinolytic drugs; antifungal drugs; antihemorrhagic drugs; antihistamines; antihyperlipidemia drugs; antihypertensive drugs; antihypertensive drugs; antiinfective drugs; anti-inflammatory drugs; antibacterial drugs; anti-migraine drugs; antidepressants. Antifungal drugs, antiemetics, antineoplastic drugs, antineutrophils, antiparasitic drugs; antiproliferative drugs; antipsychotics; antirheumatic drugs; antiseborrheic drugs; antisecretory drugs; antispasmodics; antithrombotic drugs; antiulcer drugs; antiviral drugs; appetite suppressants; blood glucose regulators; bone resorption inhibitors; bronchodilators; cardiovascular drugs; cholinergics; antidepressants; diagnostic aids; diuretics; dopamine agonists; estrogen receptor agonists; fibrinolytics; fluorescent agents; free oxygen radical scavengers; gastric acid inhibitors; gastrointestinal motility agents; glucocorticoids; hair growth stimulants; hemostatic agents; histamine H2 receptor antagonists; hormones; anticholesterolemia drugs; hypoglycemic agents; hypolipidemia drugs; antihypertensive drugs; imaging agents; immunotherapy drugs; immunomodulators; immunomodulators; immunostimulants; immunosuppressants; keratolytics; LHRH agonists; mood regulators; mucolytics; mydriatics; It may contain, but is not limited to, one or more of the following: nasal congestion decongestants; neuromuscular blocking agents; neuroprotective agents; NMDA antagonists; non-hormonal sterol derivatives; plasminogen activators; platelet activator antagonists; platelet aggregation inhibitors; psychotropic drugs; radiopharmaceuticals; scab-forming agents; sclerosing agents; sedatives; sedative-hypnotics; selective adenosine Al antagonists; serotonin antagonists; serotonin inhibitors; serotonin receptor antagonists; steroids; thyroid hormones; thyroid inhibitors; tranquilizers; amyotrophic lateral sclerosis treatment agents; cerebral ischemia treatment agents; Paget's disease treatment agents; unstable angina treatment agents; vasoconstrictors; vasodilators; wound healing agents; xanthine oxidase inhibitors. As described above, the pharmaceutical formulations disclosed herein may include, for example, diluents, binders, lubricants, surfactants, disintegrants, plasticizers, anti-tacks, opacifiers, pigments, and other auxiliary excipients. As will be understood by those skilled in the art, the precise selection of excipients and their relative amounts depends to some extent on the final oral formulation.

[0072] Pharmaceutical composition In the specific embodiments described herein, the pharmaceutical composition or transdermal preparation may include tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, as well as derivatives of these compounds. More preferably, the transdermal preparation may contain activators such as tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, and derivatives of these compounds. One embodiment described herein may be a transdermal drug delivery system that includes, but is not limited to, transdermal formulations, transdermal patches, topical formulations, microneedles, iontophoresis, and quantified transdermal sprays. Examples of transdermal formulations include liquids such as solutions, suspensions, dispersions, and emulsions, without limitation. Examples of transdermal formulations include semi-solids such as gels, ointments, emulsions, creams, suspensions, pastes, lotions, and balms, without limitation. Liquid formulations and / or gel formulations incorporated into transdermal patches are preferred. Transdermal patches may, but are not limited to, reservoir patches, matrix patches, two-layer matrix patches, multilayer matrix patches, microreservoir patches, adhesive systems, transdermal tapes, and all other transdermal drug delivery systems described in the Industry. Transdermal formulations may include polymer matrices without limitation, such as adhesive or non-adhesive matrices.

[0073] In one embodiment described herein, a transdermal patch comprises a reservoir or a transdermal formulation containing an activator such as tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof and derivatives of these compounds, and an adhesive for adhering the transdermal patch to the skin, allowing the activator such as tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof and derivatives of these compounds to pass from the transdermal patch through the patient's skin. The transdermal delivery system may be occlusive, semi-occlusive, or non-occlusive, and may be adhesive or non-adhesive. Transdermal formulations containing activators such as tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, and derivatives of these compounds, can be incorporated into a patch, which can be applied topically to the skin surface. The patch can remain on the subject for any appropriate period of time.

[0074] In one embodiment, the transdermal patch provides a constant delivery rate of the active ingredient of the transdermal patch over a predetermined period of time. In one embodiment, the predetermined period is 4 hours, 8 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 120 hours, 144 hours, 7 days, 8 to 13 days, 2 weeks, or 15 days. In further embodiments, the transdermal patch described herein provides the patient with the active ingredient of the transdermal patch at a stable absorption rate over a period of time. In some embodiments, the predetermined time is 4 hours, 8 hours, 12 hours, 15 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 120 hours, 144 hours, 7 days, 8-13 days, 2 weeks, or 15 days. In further embodiments, the transdermal patch described herein provides a patient with a constant serum level of the active ingredient of the transdermal patch over a period of time. In some embodiments, the predetermined time is 4 hours, 8 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 120 hours, 144 hours, 7 days, 8 to 13 days, 2 weeks, or 15 days. In further embodiments, the transdermal patch described herein provides a therapeutic range of plasma concentrations of the active ingredient of the transdermal patch in a patient over a certain period of time. In some embodiments, the predetermined time is 4 hours, 8 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 120 hours, 144 hours, 7 days, 8-13 days, 2 weeks, or 15 days. In further embodiments, the transdermal patches described herein can reduce variations in the dose of the active ingredient in the patient. Depending on the embodiment, the predetermined period may be 24 hours, 48 ​​hours, 72 hours, 96 hours, 120 hours, 144 hours, 7 days, 8 to 13 days, 2 weeks, or 15 days. In further embodiments, the transdermal patch described herein provides a plasma concentration of the active ingredient of the transdermal patch in a patient within a therapeutic range over a certain period of time.

[0075] In exemplary embodiments disclosed herein, the transdermal patch provides serum levels of an active agent selected from, for example, about 0.01 ng / mL, about 0.02 ng / mL, about 0.05 ng / mL, about 0.1 ng / mL, about 0.2 ng / mL, about 0.5 ng / mL, about 1 ng / mL, about 2 ng / mL, about 5 ng / mL, about 10 ng / mL, about 20 ng / mL, about 50 ng / mL, about 100 ng / mL, about 200 ng / mL, about 500 ng / mL, about 1 μg / mL, and the range therefrom. In one embodiment, the transdermal patch provides serum levels of an active agent in the range of 0.01 ng / mL to 400 ng / mL. In a further embodiment, the transdermal patch provides serum levels of an active agent in the range of 0.01 ng / mL to 100 ng / mL. In yet another embodiment, the pharmaceutical composition provides serum blood levels of the active agent ranging from 0.01 to 1 ng / ml, 1 to 100 ng / ml, 100 to 500 ng / ml, 500 to 1000 ng / ml, and 1000 to 5000 ng / ml.

[0076] In further embodiments, the pharmaceutical compositions described herein provide a plasma concentration of the active ingredient of a transdermal patch within a therapeutic range in a patient over a predetermined period of time. In exemplary embodiments disclosed herein, the pharmaceutical compositions provide serum levels of the active ingredient in the range of, for example, about 0.01 μg / mL, about 0.02 μg / mL, about 0.05 μg / mL, about 0.1 μg / mL, about 0.2 μg / mL, about 0.5 μg / mL, about 1 μg / mL, about 2 μg / mL, about 5 μg / mL, about 10 μg / mL, about 20 μg / mL, about 50 μg / mL, about 100 μg / mL, about 200 μg / mL, about 500 μg / mL, about 1 milligm / mL, about 2 milligm / mL, about 5 milligm / mL, and selected from, but not limited to, these ranges. In one embodiment, the pharmaceutical composition provides serum levels of the active ingredient in the range of 0.01 μg / mL to 400 μg / mL. In other embodiments, the pharmaceutical composition provides serum levels of the activator in the range of 0.01 μg / mL to 100 μg / mL. In yet another embodiment, the pharmaceutical composition provides serum levels of the activator in the range of 0.01 to 1 μg / mL to 1 to 100 μg / mL, 100 to 500 μg / mL, 500 to 1000 μg / mL, and 1000 to 5000 μg / mL.

[0077] Topical formulations reported in this industry include, but are not limited to, semi-solid formulations such as ointments, creams, emulsions, micro-emulsions, nano-emulsions, pastes, balms, gels, lotions, and mousses; and liquid formulations such as film-forming gels, emulsions, and micro-emulsions; and liquid formulations such as solutions, suspensions, micro-suspensions, nano-suspensions, dispersions, and nano-dispersions. Topical formulations containing activators such as sprays, aerosols, magma, tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, and derivatives of these compounds can be applied topically to the skin surface for transdermal administration.

[0078] One embodiment of the present disclosure may be a topical drug delivery system that includes, but is not limited to, topical patches, topical formulations, quantitative topical sprays, topical film-forming formulations, topical drug-containing adhesive patches, topical matrix patches, topical aerosols, and quantitative topical gels. Multilayer polymer drug matrix systems: For example, a transdermal drug delivery system is conceived in which the active substance matrix is ​​constructed using a water-soluble polymer and then coated onto an adhesive layer. Furthermore, the active substance reservoir can be prepared as a polymer matrix. In addition, the active substance reservoir can be confined by an active substance-permeable membrane on the skin-facing side of the transdermal drug delivery system, and by an active substance-impermeable layer followed by an adhesive layer on the side opposite the skin. This disclosure provides transdermal drug delivery systems comprising an active substance matrix-containing region, which is a two-layer or multi-layer active substance matrix. In other embodiments, the active substance is, in its simplest form, coarsely, colloidally, or molecularly dispersed in a solution or melt of a base polymer. In further transdermal drug delivery system manufacturing techniques, the activator is in the form of a supersaturated solution, nanoemulsion, or nanosuspension, amorphous, crystalline, or cocrystalline, and is coated with a base polymer or solubilized in a polymer using a hot-melt extrusion process.

[0079] This disclosure also describes activator matrices having a two-layer or multilayer structure, also known as multilayer drugs in adhesive patches. For example, various matrix layers may contain polymers composed of the polymers described above. In this case, the matrix layers differ from one another with respect to the polymer or pressure-sensitive or hot-melt polymer composition, activator concentration, and different penetration enhancers or solubilizers. These layers can be separated using a semipermeable membrane between two separate drug-containing adhesive layers or multiple drug-containing adhesive layers under a single backing film. The term polymer film includes, but is not limited to, pressure-sensitive adhesives and / or non-adhesive polymers.

[0080] In one embodiment, the disclosure further provides a polymer matrix formulation comprising an activator and a polymer vehicle system. The vehicle system may include a solvent (e.g., a solubilizer), a permeability-enhancing excipient and a polymer or gelling agent or thickener, and optionally an acid or base for pH adjustment.

[0081] Pretreatment: Various approaches have been used to open the barrier properties of the stratum corneum for enhanced drug penetration. Pretreatment using chemical penetration enhancers is one of the techniques employed. Pretreatment has the potential to reversibly modify the outermost layer of the skin, facilitating drug uptake. Penetration enhancers act on lipid and protein regions, either in combination or individually.

[0082] Penetration enhancers may be incorporated into formulations described herein (e.g., transdermal drug delivery systems containing the drug in an adhesive layer, as well as separate adhesive and drug-containing layers), but this may result in some incompatibility or interaction within the components. Therefore, this disclosure provides an alternative method for enhancing skin penetration with respect to preparing / pre-treating the skin with several penetration enhancers or combinations of penetration enhancers before patch application. The pretreatment application described herein includes the application of a gel / spray / solution / humectant / soaked swab / soaked cotton ball / soaked gauze to the skin prior to the application of a drug-containing product intended to be a patch. For example, the pretreatment composition may be an individual patch itself, such as CuradMediplast, a 40% salicylic acid patch, or a placebo patch containing a non-volatile component such as acrylic, silicone, or PIB adhesive, or a combination thereof with optionally added skin penetration enhancers to facilitate the delivery of the active pharmaceutical ingredient through the skin.

[0083] This disclosure provides pretreatment compositions in which a penetration enhancer is incorporated in the form of a topical administration form, such as a solution, gel, cream, spray, humectant, dipped cotton, and gauze. In further embodiments, a pretreatment composition, preferably but not limited to a gel, can be incorporated into a reservoir patch.

[0084] Topical formulations include, but are not limited to, liquids such as solutions, suspensions, dispersions, and emulsions. Examples of topical formulations include, but are not limited to, semi-solids such as gels, ointments, emulsions, creams, suspensions, pastes, lotions, and balms. Preferred topical formulations include, but are not limited to, liquid formulations and / or gel formulations incorporated into topical patches, quantitative topical systems, sachets, etc., and include, but are not limited to, polymer matrix patches such as adhesive matrix patches, non-adhesive matrices, drug-containing adhesive matrix patches, and topical matrix formulations as drug-containing adhesive matrix patches. Other topical formulations include, but are not limited to, topical gels, quantitative topical sprays, quantitative topical aerosols, and topical film-forming formulations. Topical patches may preferably include, but are not limited to, multilayer transdermal matrix systems, reservoir patches, matrix patches, two-layer matrix patches, multilayer matrix patches, microreservoir patches, adhesive systems, and topically applicable tapes.

[0085] In certain embodiments of the present disclosure, a topical patch comprises a topical formulation containing an activator such as CBD and / or THC, and derivatives of these compounds contained in a reservoir or matrix, and an adhesive that adheres the topical patch to the skin and allows the activator such as CBD and / or THC, and derivatives of these compounds, to pass from the topical patch to the patient's skin. The topical delivery system may be occlusive, semi-occlusive, or non-occlusive, and may be adhesive or non-adhesive.

[0086] Topical formulations containing activators such as CBD and / or THC, as well as derivatives of these compounds, can be incorporated into the patch, and the patch can be applied topically to the skin surface. The patch may be left on the subject for any appropriate period of time.

[0087] Transdermal and / or topical formulations of certain embodiments of the present disclosure may contain carriers or components, alone or in combination, in effective amounts, without being limited to carriers or components such as solvents, gelling agents, polymers, biodegradable polymers, penetration enhancers, emollients, skin irritation reducers, buffers, pH stabilizers, solubilizers, suspending agents, dispersants, stabilizers, plasticizers, tackifiers, surfactants, volatile chemicals, antioxidants, oxidizing agents, chelating agents, complexing agents, diluents, excipients, materials for preparing patches, materials for preparing matrix patches, and materials for preparing reservoir patches.

[0088] The activator may be dissolved, suspended, dispersed, or homogeneously mixed in the single carrier, mixture of carriers, and combination of carriers described above. Any combination of two or more drugs, such as tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, and derivatives of these compounds, can be dissolved, suspended, dispersed, or homogeneously mixed in the single carrier, mixture of carriers, and combination of carriers described above. Desired optimal transdermal and / or topical formulations, such as tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, and derivatives of these compounds, either alone or in combination thereof, may, but are not limited to, the following carriers described in Examples 1 to 12, either alone or in combination thereof. In certain embodiments, the transdermal compositions described herein are for the treatment and / or prevention and / or control of cancers such as glioblastoma and GBM.

[0089] Packaging / Processing Kit This disclosure provides a kit for convenient and effective implementation of the method relating to this disclosure. Such a kit may be suitable for the delivery of solid oral forms (e.g., tablets or capsules). Such a kit may contain several unit doses. Such a kit may include means for containing doses oriented in the order of their intended use. An example of means for containing doses in the order of intended use is a card. An example of such a kit is a "blister pack." Blister packs are well known in the packaging industry and are widely used for packaging unit formulations. If desired, the blister may be in the form of a childproof blister, i.e., a blister that is difficult for a child to open but easy for an adult to open. If necessary, memory aids may be provided, for example in the form of numbers, letters or other markings, or together with a calendar function and / or calendar insert, to specify the days and divisions of the day in a therapeutic schedule in which doses can be administered, for example, AM doses are packaged with "daytime" and PM doses; or AM doses are packaged with PM doses. Alternatively, a placebo dose, or a vitamin or dietary supplement, may be included in either the same form as the active dose or in a different form.

[0090] This disclosure provides compositions comprising preparations, formulations and / or kits comprising combinations of the above-mentioned components (including multicomponent combinations of the drugs of the present invention) that are useful as therapies for treating, preventing or improving conditions, states and diseases provided in the present invention. In one embodiment, each member of the component combination is manufactured in a separate package, kit or container; or all or a subset of the component combination is manufactured in a separate package or container. In other embodiments, the package, kit or container includes blister packaging, clamshell packaging, trays, shrink wrap, etc.

[0091] In one embodiment, the package, kit, or container includes a “blister package” (also called a blister pack or bubble pack). In one embodiment, the blister packaging consists of two or more separate compartments. This blister package consists of two separate material elements: a clear plastic cavity molded to fit the product and its blister board backing. These two elements are then joined together by a heat-sealing process that allows the product to be hung or displayed. Exemplary types of “blister packaging” include: face-seal blister packaging, ganglant blister packaging, mock blister packaging, interactive blister packaging, and slide blister packaging. Blister packs, clamshells, or trays are forms of packaging used for goods, and therefore the present invention provides blister packs, clamshells, or trays containing the composition of the present invention (e.g., a combination of activators (multi-component combination of the drug of the present invention)). Blister packs, clamshells, or trays can be designed to be non-re-sealable so that consumers can know if the package has already been opened. They are used to package goods for sale where product tampering is a concern, such as the drug of the present invention. In one embodiment, a blister pack of the present invention includes a molded PVC base having a raised area ("blister") for containing tablets, pills, etc. It includes a combination of the present invention covered with foil laminate. Tablets, pills, etc. are removed from the pack by peeling off the foil or by pressing the blister to break the foil into the tablet. In one embodiment, a special form of the blister pack is a strip pack.

[0092] In one embodiment, the blister pack also includes a packaging method in which a composition comprising a combination of the components of the present disclosure is contained between a card and transparent PVC. The PVC may be transparent so that the article (e.g., patch, pill, tablet, gel tab) can be easily seen and examined, and in one embodiment, it may be vacuum-formed around a mold so that the article fits snugly and has room to open at purchase. In one embodiment, the card is a light color and designed according to the item inside (e.g., patch, pill, tablet, gel tab), and the PVC is attached to the card using a pre-formed tab in which adhesive is placed. The adhesive may be strong enough so that the pack can be hung on a peg, but weak enough so that the joint can be torn open in this way to access the article. Sometimes, for larger items or multiple enclosed patches, pills, tablets, gel tabs, etc., the card has a perforated window for access. In one embodiment, for example, a more secure blister pack for items such as pills, tablets, gel tabs of the present invention may be used, which may include two vacuum-formed PVC sheets interlocked at the edges, having an information card inside.

[0093] In one embodiment, the blister packaging comprises at least two components (e.g., a multi-component combination of the drug of the present invention): a thermoformed "blister" containing the product (e.g., the combination of the present invention), and a "blister card" which is a printed card having an adhesive coating on its front. During the assembly process, the blister components, most commonly made from PVC, are attached to the blister card using a blister machine. Conventional blister packs can also be sealed.

[0094] As discussed herein, the products of the present invention may include packaging of the combination of therapeutic agents of the present invention, either alone or in combination, as "blister packaging," or as a plurality of packets including blister packaging with a lid, blister with a lid or blister card or packet, or shrink packaging.

[0095] In one embodiment, any of the products of the present invention, including a kit or a blister pack, includes a memory aid to help the patient remember when and how to take the drug of the present invention.

[0096] The treatment kit can be constructed in various forms known to those skilled in the art. The kit comprises at least one unit dose of the active substance for administration according to a daily regimen, and means for containing the unit dose. The treatment kit can be constructed, for example, for once daily, twice daily, three times daily, four times daily, multiple times daily, or other dosing regimens. The kit comprises means for administering the agent of the present invention daily. In one embodiment, the kit comprises about 1 to about 4 unit doses.

[0097] In one embodiment, means for containing unit doses are, for example, a card including a foldable card. This card is referred herein to as the main card, or primary card, or first card, and is distinguished from other such materials that may be associated with any further cards, circular objects, or kits. The main card can be folded with a simple fold or a double fold to exhibit a spine similar to the spine of a closed book. The main card may include a printable surface, i.e., a surface on which the product name, appropriate dosage instructions, product information, drawings, logos, memory aids, calendar functions, etc., can be printed. The main card may include means for containing the unit dose or different doses specified for different times of the day, and memory aids for administering the unit dose. The primary card may include a slit or pocket in one of the inner cardboard surfaces of the folded card, for example, if it is prepared from two or more laminated cardboard surfaces. The slit or pocket can be used to contain a removable secondary card, i.e., a second card or insert card that is not permanently attached to or fixed to the main card.

[0098] The memory aid may include a list of days of the week, i.e., Sunday, Monday, Tuesday, Wednesday, Thursday, Friday, and Saturday, with appropriate space for the patient to select and indicate on the card the days of the week they prefer to receive treatment. The memory aid may also include a list of times with appropriate space for the patient to select and indicate on the card the preferred times of the week they prefer to receive treatment (e.g., AM, PM, noon). The memory aid may also include removable stickers with appropriate pressure-sensitive adhesive to facilitate easy removal and reattachment to desired surfaces such as calendars or dayminders. The removable stickers may be placed on the main card or on a secondary card configured to be easily inserted into and removed from any slit on the main card. Furthermore, any slits may contain additional patient information and other circulars.

[0099] Other means for containing the aforementioned unit dose may include bottles and vials, where the bottle or vial includes memory aids such as printed labels for administering the unit dose(s). The labels may also include removable reminder stickers for placement on a calendar or dayminder to further help patients remember when they should take the medication or when they have taken it. The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples. [Examples] [Examples]

[0100] The transdermal and / or topical preparations described herein include, but are not limited to, C1-C20 alcohols, polyhydric alcohols, (methanol, ethanol, isopropyl alcohol, butanol, propanol, etc.), glycols, glycol derivatives, (propylene glycol, polyethylene glycol, dipropylene glycol, hexylene glycol, glycerin, etc.), (N-methyl-2-pyrrolidone, 2-pyrrolidone, etc.), (dimethyl sulfoxide, decylmethyl sulfoxide) The solvents may include, but are not limited to, sulfoxides (such as phosphates), dimethyl isosorbide, mineral oil, vegetable oil, sesame oil water, polar solvents, semi-polar solvents, non-polar solvents, volatile chemicals (ethanol, propanol, ethyl acetate, acetone, methanol, dichloromethane, chloroform, toluene, IPA, hexane), acids (such as acetic acid, lactic acid, levulinic acid), bases, pentane, dimethylformamide, butane, lipids, etc., either alone or in combination thereof. More preferably, the concentration is in the range of 0.01% to 95% w / w or w / v. The formulations described herein are available in concentrations of approximately 0.01%, 0.02%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, and 19% of the formulation. It can contain solvents at concentrations of approximately 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 75%, 76%, 80%, and 95%. In exemplary embodiments, the formulations described herein may contain solvents at concentrations of about 1-20%, about 5-25%, about 10-20%, or about 15-18%, about 30-70%, about 35-65%, about 66%, and about 40-64% w / w.In the exemplary formulations described herein, the solvent is concentrated at a concentration of about 1% to 75% by mass, preferably 2% to 30% by mass, and more preferably 5% to 20% by mass. [Examples]

[0101] The transdermal and / or topical formulations of this specification may contain, but are not limited to, natural polymers, polysaccharides and their derivatives, semi-synthetic polymers and derivatives thereof (not limited to cellulose and its derivatives) and derivatives thereof (such as methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, etc.), synthetic polymers and their derivatives (such as carboxyvinyl polymers or carbomers, not limited to those) (Carbopol 940, Carbopol 934, Carbopol 971p NF), polyethylene and its copolymers, etc. (silicates, bentonite), silicon dioxide, polyvinyl alcohol, acrylic polymers (Eudragit), acrylic acid esters, polyacrylic acid copolymers, polyacrylamide, (PVP, Coridone 30, Poloxamer), isobutylene, ethylene vinyl acetate copolymer, natural rubber, synthetic rubber, (bio-psa 4302, bio-psa Pressure-sensitive adhesives such as silicone polymers (e.g., 4202), (Duro-Tak 87-2156, Duro-Tak 387-2287, Duro-Tak 87-9301, Duro-Tak Acrylic pressure-sensitive adhesives such as 387-2051, polyisobutylene (low molecular weight polyisobutylene, medium molecular weight polyisobutylene, 35000 molecular weight polyisobutylene, etc.), acrylic copolymers, rubber adhesives, hot melt adhesives, styrene-butadiene copolymers, bentonite, all water and / or organic solvent swelling polymers, etc., without limiting them, are used individually or in combination with gelling agents and / or thickeners and / or suspending agents and / or polymers and / or adhesive polymers and / or pressure-sensitive adhesive polymers and biodegradable polymers in the formulation at approximately 0.01%, 0.02%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, and 0.9%, approximately 1%, approximately 2%, approximately 3%, approximately 4%, approximately, approximately 6%, approximately 7%, approximately 8%, approximately 9%, approximately 10%, approximately 11%, approximately 12%, approximately 13%, approximately 14%, approximately 15%, approximately 16%, approximately 17%, approximately 18%, approximately 19%, approximately 20%, approximately 21%, approximately 22%, approximately 23%, approximately 24%, approximately 25%, approximately 26%, approximately 27%, approximately 28%, approximately 29%, approximately 30%, approximately 35%, approximately 4 The formulations may contain gelling agents and / or thickeners and / or suspending agents and / or polymers and / or adhesive polymers and / or pressure-sensitive adhesive polymers in concentrations of 0%, approximately 45%, approximately 50%, approximately 55%, approximately 60%, approximately 61%, approximately 62%, approximately 63%, approximately 64%, approximately 65%, approximately 66%, approximately 67%, approximately 68%, approximately 69%, approximately 70%, approximately 75%, and approximately 80%. In exemplary embodiments, the formulations described herein may contain gelling agents and / or thickeners and / or suspending agents and / or polymers and / or adhesive polymers and / or pressure-sensitive adhesive polymers in concentrations of approximately 1-20%, approximately 5-25%, approximately 10-20%, or approximately 15-18%, approximately 30-70%, approximately 35-65%, approximately 63.13%, and approximately 40-64% w / w. The formulations described herein contain gelling agents and / or thickeners and / or suspending agents and / or polymers and / or adhesive polymers and / or pressure-sensitive adhesive polymers at a concentration of about 1% to 75% by mass, preferably 2% to 30% by mass, and more preferably 5% to 20% by mass. More preferably, the concentration is in the range of 0.1% to 70% w / w or w / v. [Examples]

[0102] The transdermal and / or topical formulations of this disclosure may contain, but are not limited to, penetration enhancers known to those skilled in the art, either alone or in combination: sulfoxides and similar chemicals, for example, (but not limited to) (dimethyl sulfoxide, dimethylacetamide, dimethylformamide, decymethylsulfoxide, dimethyl isosorbide, etc.), azone, pyrrolidone, for example, (but not limited to) (N-methyl-2-pyrrolidone, 2-pyrrolidone, etc.), esters, fatty acid esters, for example, (but not limited to) (capric acid, nathanol, dodecanol, propylene glycol, glycerol, etc.), ether alcohols, triglycerides, for example, (but not limited to) triacetin, polyoxyethylene fatty alcohol ethers, polyoxyethylene fatty acid esters, fatty alcohol esters, essential oils, surfactant enhancers, for example, (but not limited to) (brij, sodium lauryl sulfate, tween, polysorbate), terpenes, terpenoids, and the book "Percutaneous Penetration Enhancers" (Eric W. Smith, Howard). All penetration enhancers or permeation enhancers, etc., mentioned in I. Mailbach (2005. Nov., CRC press), but not limited to these, may be included, either alone or in combination thereof. The formulations described herein may contain about 0.01%, about 0.02%, about 0.05%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1%, about 2%, about 3%, about 4%, about, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, The permeation enhancer may be included in concentrations of approximately 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 75%, and 80%.In exemplary embodiments, the formulations described herein may contain permeation enhancers at concentrations of about 1-20%, about 5-25%, about 10-20%, or about 15-18%, about 30-70%, about 35-65%, about 63.13%, and about 40-64% w / w. In the exemplary formulations described herein, the permeation enhancer is at a concentration of about 1%-75% by mass, preferably 2%-30% by mass, and more preferably 5%-20% by mass. More preferably, it is in the range of 0.01%-95% w / w or w / v. [Examples]

[0103] The transdermal and / or topical formulations described herein may include, individually or in combination, plasticizers known to those skilled in the art, such as: glycerol and its esters, phosphate esters, glycol derivatives, sugar alcohols, sebacate esters, citrate esters, tartrate esters, adipine salts, phthalate esters, triacetin, oleate esters, and all plasticizers that can be used in transdermal drug delivery systems as mentioned in the book "Handbook of Plasticizers" (George Wypych, 2004, Chem Tec Publishing). The formulations described herein are approximately 0.01%, approximately 0.02%, approximately 0.05%, approximately 0.1%, approximately 0.2%, approximately 0.3%, approximately 0.4%, approximately 0.5%, approximately 0.6%, approximately 0.7%, approximately 0.8%, approximately 0.9%, approximately 1%, approximately 2%, approximately 3%, approximately 4%, approximately, approximately 6%, approximately 7%, approximately 8%, approximately 9%, approximately 10%, approximately 11%, approximately 12%, approximately 13%, approximately 14%, approximately 15%, approximately 16%, approximately 17%, and approximately 18% of the formulation. It can be included in plasticizers at concentrations of approximately 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 75%, and 80%. The formulations described herein may contain plasticizers at concentrations of about 1-20%, about 5-25%, about 10-20%, or about 15-18%, about 30-70%, about 35-65%, about 63.13%, and about 40-64% w / w. More preferably, in exemplary embodiments, the plasticizer in the formulations described herein is at a concentration of about 1%-75% by mass, preferably 2%-30% by mass, and more preferably 5%-20% by mass. More preferably, it is in the range of 0.01%-95% w / w or w / v. [Examples]

[0104] The transdermal and / or topical formulations of this specification may include, individually or in combination, the following substances known to those skilled in the art: petrolatum, lanolin, mineral oil, dimethicone, zinc oxide, glycerin, propylene glycol, and others, as emollients, moisturizers, skin irritants, and similar compounds or chemical substances known to those skilled in the art. More preferably, these are present in the range of 0.01% to 95% w / w or w / v. The formulations described herein are approximately 0.01%, approximately 0.02%, approximately 0.05%, approximately 0.1%, approximately 0.2%, approximately 0.3%, approximately 0.4%, approximately 0.5%, approximately 0.6%, approximately 0.7%, approximately 0.8%, approximately 0.9%, approximately 1%, approximately 2%, approximately 3%, approximately 4%, approximately, approximately 6%, approximately 7%, approximately 8%, approximately 9%, approximately 10%, approximately 11%, approximately 12%, approximately 13%, approximately 14%, approximately 15%, approximately 16%, approximately 17%, approximately 18%, approximately 19%, and approximately 20% of the formulation. It may contain emollients, moisturizers, skin irritation reducers and similar compounds in concentrations of approximately 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 75%, and 80%. The formulations described herein may contain emollients, moisturizers, skin irritation reducers and similar compounds in concentrations of about 1-20%, about 5-25%, about 10-20%, or about 15-18%, about 30-70%, about 35-65%, about 63.13%, and about 40-64% w / w. The emollients, moisturizers, skin irritation reducers and similar compounds in the formulations described herein have a concentration of about 1%-75% by mass, preferably 2%-30% by mass, more preferably 5%-20% by mass, and more preferably in the range of 0.01%-95% w / w or w / v. [Examples]

[0105] The transdermal and / or topical formulations described herein include the following, which are known to those skilled in the art: polysorbates, including but not limited to (polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, etc.); spans, including but not limited to (span 80, span 20, etc.); surfactants, including but not limited to (anionic, cationic, nonionic, amphoteric); propylene glycol monocaprylate type I; propylene glycol monocaprylate type II; propylene glycol dicaprylate; medium-chain Triglycerides, propylene glycol monolaurate type II, linoleyl polyoxyl 6-glyceride, caprylglyceride, oleyl 10-polyoxyl-1-6-glyceride, lauroyl polyoxyl 6-glyceride, polyglyceryl-3-dioleic acid, caprylocaproyl polyoxyl-8-glyceride, cyclodextrin, etc., can be included individually or in combination therewith as solubilizers, surfactants, emulsifiers, dispersants, diluents, and similar compounds or chemical substances known to those skilled in the art. More preferably, the concentration is in the range of 0.01% 95% w / v or w / v. The formulations described herein are available in concentrations of approximately 0.01%, 0.02%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, and 2% of the formulation. It may contain solubilizers, surfactants, emulsifiers, dispersants, diluents, and similar compounds or chemical substances in concentrations of 2%, approximately 23%, approximately 24%, approximately 25%, approximately 26%, approximately 27%, approximately 28%, approximately 29%, approximately 30%, approximately 35%, approximately 40%, approximately 45%, approximately 50%, approximately 55%, approximately 60%, approximately 61%, approximately 62%, approximately 63%, approximately 64%, approximately 65%, approximately 66%, approximately 67%, approximately 68%, approximately 69%, approximately 70%, approximately 75%, and approximately 80%.The formulations described herein may contain solubilizers, surfactants, emulsifiers, dispersants, diluents and similar compounds or chemical substances in concentrations of about 1-20%, about 5-25%, about 10-20%, or about 15-18%, about 30-70%, about 35-65%, about 63.13%, and about 40-64% w / w. The solubilizers, surfactants, emulsifiers, dispersants, diluents and similar compounds or chemical substances in the formulations described herein have a concentration of about 1%-75% by mass, preferably 2%-30% by mass, more preferably 5%-20% by mass, and more preferably in the range of 0.01%-95% w / w or w / v. [Examples]

[0106] Different technologies and components can be used to enhance the stability and / or solubility of the active ingredient in the formulation, but are not limited to coating, encapsulation, microencapsulation, nanoencapsulation, freeze-drying, chelating agents, complexing agents, etc. [Examples]

[0107] The transdermal and / or topical formulations of this specification may include, alone or in combination therewith, pH buffering aids and pH stabilizers known to those skilled in the art, as well as compounds similar thereto, which help maintain the pH of the formulation preferably within the range of 4.0 to 8.0. More preferably in the range of 0.01% to 30% w / w or w / v. The formulations described herein are approximately 0.01%, approximately 0.02%, approximately 0.05%, approximately 0.1%, approximately 0.2%, approximately 0.3%, approximately 0.4%, approximately 0.5%, approximately 0.6%, approximately 0.7%, approximately 0.8%, approximately 0.9%, approximately 1%, approximately 2%, approximately 3%, approximately 4%, approximately, approximately 6%, approximately 7%, approximately 8%, approximately 9%, approximately 10%, approximately 11%, approximately 12%, approximately 13%, approximately 14%, approximately 15%, approximately 16%, approximately 17%, approximately 18%, approximately 19%, approximately 20%, This may include pH buffering agents and pH stabilizers in concentrations of approximately 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 75%, and 80%, as well as similar compounds. In exemplary embodiments, the formulations described herein may include pH buffering aids and pH stabilizers, as well as analogous compounds, in concentrations of about 1-20%, about 5-25%, about 10-20%, or about 15-18%, about 30-70%, about 35-65%, about 63.13%, and about 40-64% w / w. In the exemplary formulations described herein, the pH buffering aids and pH stabilizers, as well as analogous compounds, are concentrated at a concentration of about 1%-75% by mass, preferably 2%-30% by mass, and more preferably 5%-20% by mass. More preferably, the concentration is in the range of 0.01%-30% w / w or w / v. [Examples]

[0108] The transdermal and / or topical formulations of this specification may contain antioxidants known to those skilled in the art, such as (sodium metabisulfite, citric acid, ascorbic acid, BHA, BHT), oxidizing agents, stabilizers, discolorants, preservatives, and similar compounds or chemical substances known to those skilled in the art that are useful in obtaining stabilizers, either alone or in combination thereof. More preferably, the concentration is in the range of 0.01% to 50% w / w or w / v. The formulations described herein are approximately 0.01%, approximately 0.02%, approximately 0.05%, approximately 0.1%, approximately 0.2%, approximately 0.3%, approximately 0.4%, approximately 0.5%, approximately 0.6%, approximately 0.7%, approximately 0.8%, approximately 0.9%, approximately 1%, approximately 2%, approximately 3%, approximately 4%, approximately, approximately 6%, approximately 7%, approximately 8%, approximately 9%, approximately 10%, approximately 11%, approximately 12%, approximately 13%, approximately 14%, approximately 15%, approximately 16%, approximately 17%, approximately 18% of the formulation. Antioxidants can be included in concentrations of approximately 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 75%, and 80%. The formulations described herein may contain antioxidants at concentrations of about 1-20%, about 5-25%, about 10-20%, or about 15-18%, about 30-70%, about 35-65%, about 63.13%, and about 40-64% w / w. The antioxidants in the formulations described herein have a concentration of about 1%-75% by mass, preferably 2%-30% by mass, more preferably 5%-20% by mass, and more preferably in the range of 0.01%-50% w / w or w / v. [Examples]

[0109] The transdermal and / or topical formulations described herein can be formulated in dosage forms known to those skilled in the art, such as ointment bases, cream bases, and gel bases. [Examples]

[0110] Materials for preparing the patch-type transdermal and / or local delivery systems described herein include, but are not limited to, the following known to those skilled in the art: for example, reservoir patches, matrix patches, adhesive matrix patch agents, film-forming formulations, film-forming sprays, microdosing oral patches, etc., and may include polymers, copolymers, derivatives, support films, release films, release liners, etc., either alone or in combination thereof. Pressure-sensitive adhesives (e.g., silicone polymers, rubber-based adhesives, acrylic polymers, acrylic copolymers, polyisobutylene, acrylic acid-isooctyl acrylate copolymers, hot-melt adhesives, polybutylene, etc., but not limited thereto), backing films (e.g., ethylene vinyl acetate copolymers, vinyl acetate resins, polyurethanes, polyvinyl chlorides, metal foils, polyesters, aluminized films, polyethylene, etc., but not limited thereto), release films (e.g., microporous polyethylene films, microporous polypropylene films, speed-controlled ethylene vinyl acetate copolymer films, etc., but not limited thereto), release liners (e.g., siliconeized polyester films, fluororesin-coated polyester films, polyester films, siliconeized polyethylene terephthalate films, etc., but not limited thereto), tapes, etc., but not limited thereto. The transdermal and / or topical formulations and / or transdermal delivery systems and / or topical delivery systems described herein can deliver, for example, at least therapeutically effective amounts of active agents, such as tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, and derivatives of these compounds, either alone or in combination, into human plasma necessary for the treatment and / or prevention and / or control of chronic pain. The sustained-release formulations and / or transdermal and / or topical formulations and / or transdermal delivery systems of this disclosure can deliver at least therapeutically effective amounts of active agents, such as tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, and derivatives of these compounds, either alone or in combination, into human plasma necessary for the treatment and / or prevention and / or control of cancers such as glioblastoma and GBM.The dosage of therapeutically effective active agents such as tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, and derivatives of these compounds, refers to the therapeutic concentration in human plasma required for the treatment and / or prevention and / or control of cancers such as glioblastoma and GBM. Furthermore, the exact therapeutically effective dose of tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, and derivatives of these compounds in transdermal formulations, topical formulations, or transdermal delivery systems may be determined by those skilled in the art based on factors such as the patient's condition, but is not limited thereto. Transdermal formulations, topical formulations, or transdermal delivery systems may be available in different dosage intensities and patch sizes to achieve optimal therapeutic outcomes based on the patient's requirements. In yet another embodiment, the transdermal formulations and / or topical formulations and / or transdermal delivery systems of this disclosure may deliver at least a therapeutically effective dose of tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, and derivatives of these compounds. Therapeutically effective tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, and derivatives of these compounds refer to highly purified therapeutic concentrations of these compounds in human plasma necessary for the treatment and / or prevention and / or control of cancers such as glioblastoma and GBM. Transdermal formulations or transdermal patches of active agents such as tetrahydrocannabinol (THC), cannabidiol (CBD), or combinations thereof, and derivatives of these compounds may be applied to the skin surface in any of the following dosing regimens, such as once daily, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every eight to thirteen days, once every two weeks, or once every fifteen days. [Examples]

[0111] Synthetic cannabidiol (CBD) preparations for transdermal delivery (preparation numbers 047-055) were prepared by mixing the components shown in Table 1.

[0112] [Table 1] The above components (Table 1) are blended by stirring for 18 hours, and then the matrix is ​​spread uniformly to a thickness of 0.5 mm on an 8 × 14 inch sheet of release liner (e.g., 3M 9744) using a commercially available benchtop spreader. Next, the sheet is placed in an oven at 86 F for 120 minutes to evaporate the ethyl acetate adhesive solvent. Then, an opaque backing film with low oxygen permeability (e.g., 3M 9730 NR film) is carefully applied by hand to suppress photodegradation and oxidative degradation and avoid the formation of bubbles and voids. Patches (1.76 sq cm) are cut using a circular die (1.5 inch diameter) for subsequent study. After drying, the drug adhesive matrix has a surface density of 2–30 mg / sq cm and contains 5% w / w CBD. The prepared formulations were then subjected to release tests as follows: After weighing the patches (n=3), the release liner was removed, and the patches were placed in 20 ml scintillation vials containing 15 ml of acceptor medium. The acceptor medium was a pH 7.4 PBS solution with 0.5% Brij(O)20. The vials were placed on rollers overnight at 20 RPM. Samples were collected every 24 hours up to 72 hours, with the medium completely replaced each time. The samples were then subjected to HPLC to determine the percentage of CBD released from the different formulations. The prepared formulations were also analyzed for the uniformity of drug content. Patches (n=3) were weighed for each formulation, the release liner was removed, and the patches (including the release liner) were placed in 20 ml scintillation vials with 15 ml of IPA:ethanol (190 proof) (50:50) solution. The vials were then placed on a roller at 20 RPM and left overnight. Samples were removed from each vial and analyzed by HPLC to determine the drug content of each formulation.

[0113] [Table 2] The percentage of CBD released via the matrix system was measured for a minimum of 48 hours (2 days), and the results are shown in Table 3.

[0114] [Table 3] Drug content testing showed that the CBD recovery rate (%) in extraction was 96-107% for all manufactured formulations. Furthermore, peel tests showed that silicone adhesive 4501 exhibited over 90% peeling within the first 24 hours. Based on the release profile, the best adhesives for CBD formulations are as follows: BIOPSA-4501 > 2054 = 2194 > 2074 > 2516 > 2852 = 2287 > 9301. Release tests showed that functional groups and crosslinking agents affect CBD release from acrylic adhesives. According to these tests, acrylic adhesives containing -COOH functional groups along with crosslinking agents showed the maximum CBD release from all acrylic adhesive patches. [Examples]

[0115] Further synthetic cannabidiol (CBD) formulations for transdermal delivery (formulation numbers 057-064) were prepared by mixing the components shown in Table 4.

[0116] [Table 4] A synthetic cannabidiol preparation (057-064) for transdermal delivery was prepared using the same procedure as described in Example 12. Next, the prepared transdermal formulations were subjected to flux measurement tests as follows: Human cadaveric skin, stored at -80°C, was thawed at room temperature in phosphate-buffered saline (PBS) and visually inspected for defects before use in the test. The transdermal flux was then measured using a standard Franz diffusion cell consisting of a cylindrical donor compartment with a capacity of 13 mL and a separate cylindrical receptor compartment with a water jacket. The human cadaveric skin was fixed between the two compartments with the dermal side facing the receptor compartment. The donor compartment was filled with the transdermal CBD formulation prepared as described above. The receptor compartment was filled with receptor medium, maintained at a constant temperature, and constantly stirred to collect CBD as it diffused through the skin into the receptor compartment. It is important to ensure that the receptor solution is always in contact with the skin. The receptor compartment was emptied at 24-hour intervals for the CBD assay and replaced with fresh receptor solution. To maintain sink conditions in the receptor compartment, it is important to keep the CBD concentration in the receptor compartment below 10% of its solubility. The experimental conditions are shown in Table 5.

[0117] [Table 5] The flux of CBD passing through human cadaver skin was measured for a minimum of 96 hours (4 days), and the results of the flux measurements are provided in Table 6. After the flow test was completed, the used patches were carefully removed, and CBD was extracted from them using IPA:ethanol (50:50). Human cadaver skin was also immersed in IPA:ethanol (50:50) to extract CBD from it. The samples were analyzed using HPLC. The data in Table 6 show the amount of CBD present in the skin and the remaining patches.

[0118] [Table 6] [Examples]

[0119] Further synthetic cannabidiol (CBD) formulations for transdermal delivery (formulation numbers 102-106) were prepared by mixing the components shown in Table 7.

[0120] [Table 7] Synthetic cannabidiol formulations for transdermal delivery (102-106) were prepared using the same procedure as described in Example 12. In vitro flux testing was performed using the same procedure as described in Example 13. The flux of CBD through human cadaver skin was measured over a minimum period of 144 hours (6 days), and the flux measurement results are provided in Table 8.

[0121] [Table 8] [Examples]

[0122] Further synthetic cannabidiol (CBD) formulations for transdermal delivery (formulation number 060) were prepared by mixing the components shown in Table 9.

[0123] [Table 9] A synthetic cannabidiol preparation (060) for transdermal delivery was prepared by the same procedure as described in Example 12. In vitro flux tests were performed using the same procedure as described in Example 13. The effects of the receptor media (RM) were evaluated using several different RMs: 1) 0.5% w / w Brij 0 20 in water, 2) 1% w / w Brij 0 20 in water, 3) 0.5% w / w Brij 0 20 water:ethanol (50:50), 4) 0.5% w / w Brij 0 20 water:ethanol (90:10), 5) 0.5% w / w Brij 0 20 water:ethanol (80:20), 6) 0.5% w / w Brij 0 20 water:ethanol (70:30), and 7) 0.5% w / w Brij 0 20 water:PEG400 (60:40). The flux of CBD passing through human cadaver skin was measured over a minimum period of 168 hours (7 days), and the flux measurement results are provided in Tables 10, 11, and 12.

[0124] [Table 10]

[0125] [Table 11]

[0126] [Table 12] [Examples]

[0127] Further synthetic cannabidiol (CBD) formulations for transdermal delivery (formulation numbers 102 and 104) were prepared by mixing the components shown in Table 13.

[0128] [Table 13] Synthetic cannabidiol formulations for transdermal delivery (102 and 104) were prepared by the same procedure as described in Example 12. In vitro flux testing was performed using the same procedure as described in Example 13. The effect of the receptor medium (RM) was evaluated using two different RMs: 1) 0.5% w / w Brij 0 20 in water, and 2) 0.5% w / w Brij 0 20 in water:ethanol (50:50). The flux of CBD through human cadaver skin was measured over a minimum period of 120–144 hours (5–6 days), and the flux measurement results are provided in Table 14.

[0129] [Table 14] [Examples]

[0130] (solution) Synthetic cannabidiol (CBD) preparations for transdermal delivery (preparation numbers 001, 002, 003, 004, and 005) were prepared by mixing the components shown in Table 15.

[0131] [Table 15] All the ingredients in Table 15, except for CBD, were mixed together with stirring for 18 hours. Next, CBD was added to the excipient mixture to prepare the final transdermal formulation. Next, the prepared transdermal formulations were subjected to flux measurement tests as follows: Human cadaveric skin, stored at -80°C, was thawed at room temperature in phosphate-buffered saline (PBS) and visually inspected for defects before use in the test. The transdermal flux was then measured using a standard Franz diffusion cell consisting of a cylindrical donor compartment with a capacity of 13 mL and a separate cylindrical receptor compartment with a water jacket. The human cadaveric skin was fixed between the two compartments with the dermal side facing the receptor compartment. The donor compartment was filled with the transdermal CBD formulation prepared as described above. The receptor compartment was filled with receptor medium, maintained at a constant temperature, and constantly stirred to collect CBD as it diffused through the skin into the receptor compartment. It is important to ensure that the receptor solution is always in contact with the skin. The receptor compartment was emptied at 24-hour intervals for the CBD assay and replaced with fresh receptor solution. To maintain sink conditions in the receptor compartment, it is important to keep the CBD concentration in the receptor compartment below 10% of its solubility. The experimental conditions are shown in Table 5.

[0132] [Table 16] The flux of CBD passing through human cadaver skin was measured over a minimum period of 144 hours (6 days), and the flux measurement results are provided in Table 16.

[0133] [Table 17] [Examples]

[0134] (solution) Further synthetic cannabidiol (CBD) formulations for transdermal delivery (formulation numbers 006-014) were prepared by mixing the components shown in Table 17.

[0135] [Table 18] A synthetic cannabidiol preparation (006-014) for transdermal delivery was prepared using the same procedure as described in Example 6. Flux measurement was also performed as described in Example 17. The experimental conditions were the same as those shown in Table 5 of Example 17. The flux of CBD transmitted through human cadaver skin was measured for a minimum of 48 hours, and the results of the flux measurement test are provided in Table 18.

[0136] [Table 19] [Examples]

[0137] (solution) Further synthetic cannabidiol (CBD) formulations for transdermal delivery (formulation numbers 160, 162, 175, 176, 177) were prepared by mixing the components shown in Table 19.

[0138] [Table 20] A synthetic cannabidiol preparation (160-177) for transdermal delivery was prepared using the same procedure as described in Example 17. Flux measurement was also performed as described in Example 17. The experimental conditions were the same as those shown in Table 5 of Example 17. The flux of CBD passing through human cadaver skin was measured over a minimum period of 120 hours, and the results of the flux measurement test are provided in Table 20.

[0139] [Table 21] Although the present invention has been described in detail with reference to specific embodiments, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the spirit and scope of the invention.

Claims

1. below: from about 3% to about 15% of an active agent selected from the group consisting of cannabidiol (CBD), synthetic forms thereof, biosynthetic forms thereof, free base forms thereof, salts thereof, isomers thereof, amorphous forms thereof, derivatives thereof, and combinations thereof; from about 3% to about 15% of an active agent selected from the group consisting of tetrahydrocannabinol (THC), synthetic forms thereof, biosynthetic forms thereof, free base forms thereof, salts thereof, isomers thereof, amorphous forms thereof, derivatives thereof, and combinations thereof; and combinations thereof; A transdermal pharmaceutical composition comprising at least one active agent selected from the group consisting of: In addition, the following: From about 0% to about 97% of at least one solvent; From about 0% to about 97% of at least a surfactant; Optionally, from about 0% to about 97% of at least one permeation enhancer; and / or In some cases, from about 0% to about 97% adhesive and / or polymer and applied for a period selected from the group consisting of once a day, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, and once every ten days; A transdermal pharmaceutical composition.

2. 2. The transdermal pharmaceutical composition according to claim 1, which is formulated as a transdermal liquid formulation, a transdermal semi-solid formulation, a transdermal gelling agent, a transdermal polymer matrix formulation, a transdermal adhesive matrix formulation, a transdermal film-forming gelling agent, a transdermal film-forming spray formulation, a multi-layer transdermal matrix system, a formulation in an infusion pump, or a transdermal drug-in adhesive type matrix formulation.

3. 3. The transdermal pharmaceutical composition of claim 1 or 2, wherein administration to a patient by a route selected from the group consisting of parenteral, intravenous, subcutaneous, intramuscular, intrathecal, oral, buccal, mucosal, nasal, rectal, vaginal, transdermal, implantable, topical, and combinations thereof, results in continuous sustained delivery.

4. 4. The transdermal pharmaceutical composition of claim 1, wherein intravenous or subcutaneous injection provides continuous sustained delivery.

5. The transdermal pharmaceutical composition according to any one of claims 1 to 4, which provides continuous sustained delivery by subcutaneous injection.

6. The transdermal pharmaceutical composition according to any one of claims 1 to 5, wherein continuous sustained delivery is provided by an infusion pump device.

7. The transdermal pharmaceutical composition according to any one of claims 1 to 6, wherein continuous sustained delivery is provided by an ambulatory / portable infusion pump worn by the patient and capable of using replaceable cartridges.

8. The transdermal pharmaceutical composition according to any one of claims 1 to 7, wherein continuous sustained delivery is achieved by a patch pump or a micropump.

9. The transdermal pharmaceutical composition according to any one of claims 1 to 8, which is formulated as a transdermal patch.

10. The transdermal pharmaceutical composition according to any one of claims 1 to 9, formulated as a multi-layer transdermal matrix system, a metered dose transdermal gel, a metered dose transdermal spray, a film-forming gel, a film-forming spray or a metered dose aerosol.

11. The transdermal pharmaceutical composition according to any one of claims 1 to 10, which is formulated as a microneedle.

12. Cancers include endometrial cancer, breast cancer, ovarian cancer, cervical cancer, fallopian tube cancer, testicular cancer, primary peritoneal cancer, colon cancer, colorectal cancer, small intestine cancer, anogenital squamous cell carcinoma, melanoma, renal cell carcinoma, lung cancer, non-small cell lung cancer, stomach cancer, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, esophageal squamous cell carcinoma, stomach cancer, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, head and neck cancer, 12. The transdermal pharmaceutical composition according to any one of claims 1 to 11 for the treatment and / or prevention and / or control of cancer in a patient selected from the group consisting of: squamous cell carcinoma of the esophagus, prostate cancer, pancreatic cancer, mesothelioma, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, head and neck cancer, squamous cell carcinoma of the head and neck, prostate cancer, pancreatic cancer, mesothelioma, Merkel cell carcinoma, sarcoma, glioblastoma, GBM, blood cancers such as multiple myeloma, B cell lymphoma, T cell lymphoma, Hodgkin's lymphoma / primary mediastinal B cell lymphoma, chronic myeloid leukemia.

13. 13. The transdermal pharmaceutical composition of any one of claims 1 to 12, wherein the active agent is synthetically produced and has a purity of about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.75%, or 100% (w / w) or more prior to addition to the pharmaceutical composition.

14. Use of a transdermal pharmaceutical composition according to any one of claims 1 to 13 for use in a method for the treatment and / or prevention and / or control of cancer in a patient, said method comprising: - selecting a patient in need of treatment and / or prevention and / or control of cancer, - topically applying a transdermal pharmaceutical composition according to any one of claims 1 to 13, and applying the transdermal pharmaceutical composition for a period selected from the group consisting of once a day, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, and once every ten days.

15. Cancers include endometrial cancer, breast cancer, ovarian cancer, cervical cancer, fallopian tube cancer, testicular cancer, primary peritoneal cancer, colon cancer, colorectal cancer, small intestine cancer, anogenital squamous cell carcinoma, melanoma, renal cell carcinoma, lung cancer, non-small cell lung cancer, stomach cancer, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, esophageal squamous cell carcinoma, stomach cancer, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, head and neck cancer, 15. The use according to claim 14 for the treatment and / or prevention and / or control of cancer in a patient selected from the group consisting of cervical cancer, head and neck squamous cell carcinoma, prostate cancer, pancreatic cancer, mesothelioma, gallbladder cancer, liver cancer, thyroid cancer, laryngeal cancer, salivary gland cancer, esophageal cancer, head and neck cancer, head and neck squamous cell carcinoma, prostate cancer, pancreatic cancer, mesothelioma, Merkel cell carcinoma, sarcoma, glioblastoma, GBM, blood cancers such as multiple myeloma, B cell lymphoma, T cell lymphoma, Hodgkin's lymphoma / primary mediastinal B cell lymphoma, chronic myeloid leukemia.

16. 16. The use according to claim 14 or 15, wherein the cancer is glioblastoma or GBM.

17. The use according to any one of claims 14 to 16, further comprising providing a constant delivery rate of the active agent of said transdermal pharmaceutical composition over a period of time.

18. The use according to any one of claims 14 to 17, further comprising reaching a constant blood serum level of the active agent of said transdermal pharmaceutical composition over a period of time.

19. The use according to any one of claims 14 to 18, further comprising providing a plasma concentration of the active agent of said transdermal pharmaceutical composition in the therapeutic range of about 0.01 ng / mL to about 500 ng / mL.

20. The use according to any one of claims 14 to 19, wherein the transdermal pharmaceutical composition is continuously and sustainedly delivered to a patient by intravenous or subcutaneous infusion.

21. The use according to any one of claims 14 to 20, wherein the transdermal pharmaceutical composition is continuously and sustainedly delivered to the patient by an ambulatory / portable infusion pump worn by the patient and capable of using replaceable cartridges.